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ABSTRACT 
The insulin-like growth factor (IGF) system is a well-studied growth 
regulatory pathway implicated in breast cancer tumorigenicity and drug 
resistance. The pivotal members of IGF system, the type I insulin-like growth 
factor (IGF1R) and insulin receptor (InsR) are homologous receptors necessary 
for signal transduction by their cognate ligands insulin, insulin-like growth factor-I 
and –II. A number of drugs, including monoclonal antibodies (mAbs) directed 
against IGF1R, small molecule tyrosine kinase inhibitors (TKIs) and IGF ligand 
neutralizing antibodies have been developed and tested in clinical trials. Early 
trials suggested benefits in delaying tumor progression, unfortunately, none of 
the anti-IGF1R mAbs has, thus far, shown significant benefits in phase III clinical 
trials. Although preclinical studies of anti-IGF1R mAbs showed promising results 
using endocrine-sensitive models, these antibodies were evaluated in breast 
cancer patients with endocrine-resistant tumors. When our group generated 
endocrine-resistant breast cancer models, we showed that IGF1R expression 
was lacking and anti-IGF1R mAb treatment was inefficacious in treating these 
endocrine-resistant cells. Inaccurate recapitulation of human diseases explains 
the disappointing outcomes of the trials. This finding also suggests that IGF1R 
inhibition is not an appropriate treatment in treating breast cancer patients whom 
are resistant to endocrine treatments.  
Unlike IGF1R, InsR expression is not affected in the endocrine-resistant 
breast cancer model. Several studies have shown a shift in gene signatures from 
IGF- to insulin-mediated growth and differentiation in the absence of IGF1R. Our 
group has shown an increase of insulin sensitivity in breast cancer cells when 
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IGF1R is downregulated and insulin/InsR alone is sufficient to drive metastasis 
and tumor growth in vivo. However, InsR has been intentionally avoided as a 
potential target in cancer therapy due to its major function in glucose 
homeostasis. There are, currently no InsR-specific inhibitor or molecular 
diagnostics available. This reason has become the motivation for my work.  
The first section of the work examines the roles of InsR and efficacy of 
InsR inhibition in endocrine-resistant breast cancer. The model we used was a 
tamoxifen resistant (TamR) cells derived from estrogen receptor positive breast 
cancer cell lines.  These TamR cells did not simply lose IGF1R expression and 
function, but also gained sensitivity to insulin stimulation compared to their 
parental cells. We used three different targeting mechanisms to disrupt the 
functions of InsR: 1.) InsR short hairpin RNA (shIR) to knock down endogenous 
InsR expression, 2.) a small InsR-blocking peptide, S961 and 3.) an InsR down-
regulator mAb (clone 83-7). These methods showed consistent results that 
suppression of InsR function in TamR cells successfully blocked insulin-mediated 
signaling, monolayer proliferation, cell cycle progression and anchorage-
independent growth. This strategy, however was not effective in the parental 
cells, which were sensitive to endocrine treatments, likely because of the 
presence of IGF1R/InsR hybrid receptors. Down-regulation of IGF1R with 
monoclonal antibody in conjunction with shIR or S961 was more effective in 
blocking IGF- and insulin-mediated signaling and growth in the parental cells 
compared with single-receptor targeting alone. Our finding showed TamR cells 
were stimulated by InsR and were not sensitive to IGF1R inhibition, whereas in 
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tamoxifen-sensitive parental cells, the presence of both receptors, especially 
hybrid receptors, allowed cross-reactivity of ligand-mediated activation and 
growth. Surprisingly, the synergistic inhibitory effects were not achievable with 
anti-IGF1R and anti-InsR mAbs in the parental cells. When this combination 
treatment was tested in triple-negative breast cancer cells, an additive inhibition 
of ligand-mediated signaling was observed, especially in the samples treated 
with IGF-II, suggesting that they may potentially benefit from the combinational 
IGF1R/InsR therapy. Although the signaling result of IGF1R/InsR blocking 
antibodies seems promising in triple-negative breast cancer, no functional assay 
has yet been done to prove their efficacy.  
The second section of my dissertation focuses on the generation and 
characterization of InsR-evolved small protein scaffolds based on the T7 phage 
Gene 2 protein (Gp2). Gp2 is one of the potential small protein scaffolds for 
ligand engineering and has the capable for mutation to generate new binding 
functions. Our long-term goal is to create effective InsR inhibitors and/or 
diagnostic tools. Using yeast surface display and directed evolution, we identified 
three Gp2 variants, known as Gp2 #1, #5 and #10 with low nanomolar binding 
affinity to cell-surface InsR with weak cross-reactivity to IGF1R of Gp2#1. These 
Gp2 variants inhibited insulin-mediated monolayer proliferation in both endocrine-
sensitive and -resistant breast cancer, but did not down-regulate InsR 
expression. Gp2 #5 and Gp2#10 disrupted InsR function by inhibiting ligand-
induced receptor activation. In contrast, Gp2#1 did not block InsR 
phosphorylation. Notably, Gp2#1 binding was enhanced by pre-treatment of cells 
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with insulin suggesting a unique receptor-ligand binding mode. These Gp2 
variants are the first non-immunoglobulin protein scaffolds to target insulin 
receptor and present compelling opportunity for modulation of InsR signaling.   
Taken together, targeting both IGF1R and InsR is optimal in endocrine-
sensitive, endocrine-resistant breast cancer and potentially triple-negative breast 
cancer to fully suppress the IGF system. Since double inhibition using mAbs 
might not be an ideal approach in endocrine-sensitive breast cancer, future 
studies using one of the Gp2 variants as alternative options, either as a single or 
in combination with other agents may provide some insights with regards to IGF 
targeting in breast cancer.  
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Statistical facts and therapeutic options in breast cancer 
 Breast cancer is the most frequently diagnosed cancer and the second 
leading cause of cancer death among women in the United States. According to 
American Cancer Society, an estimated 61,000 cases of in situ, more than 
249,000 invasive new cases and 40,000 deaths are expected in 2016. About one 
in eight women will develop breast cancer at some point in their life time. 
Although the incidence is prevalent, the survival rate for breast cancer is one of 
the highest among the solid cancers. Death rate from breast cancer has declined 
by 38% since around the 1990s, with larger decreases in women younger than 
50 years old due to improvements in early detection and treatments. The chance 
that a woman will die from breast cancer is 3% [1]. The majority of the breast 
cancer deaths was due to recurrence and metastasis. Statistics from National 
Cancer Institute’s Surveillance, Epidemiology and End Results (SEER) database 
show that breast cancer found localized has a five-year relative survival rate of 
98.8%. As it spreads to regional lymph nodes, the five-year survival rate drops to 
85.2% and further decreases to 26.3% when the cancer metastasizes to distant 
parts of the body [2].  
 The standard treatments for breast cancer include at least one of the 
following: mastectomy/lumpectomy, radiation therapy, chemotherapy, endocrine 
therapy and/or targeted therapy, depending on the stages, subtypes and 
molecular status of the tumors. Surgery and radiation therapy are both effective 
treatments in removing and destroying breast tumors. Chemotherapy is one of 
the oldest methods that has been used to treat cancer by killing highly dividing 
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cells. This traditional method has been proven effective, however, cytotoxicity is 
inevitable due to its indiscriminating killing effects on normal healthy cells. 
Moreover, as these neoplastic cells are not completely killed or suppressed, this 
residual population enables regrowth of tumors that no longer respond to a wide 
variety of drugs and ultimately ensue resistance to cancer drugs [3]. Thus, 
identifying new therapies, either alone or in combination with traditional 
therapies, to treat breast cancer is crucial.  
 Endocrine and targeted therapies are relatively newer therapies as they 
target specific characteristics in cancer cells, in hope to control tumor growth with 
reduced potential cytotoxic effects. Often, cancer cells display evaded 
programmed cell death, enhanced growth signals and proliferative properties via 
elevated or dysregulated hormonal or growth factor pathways. Targeting these 
pathways may be an alternative approach to the traditional methods that have 
not been very successful. One good example of targeted therapies in breast 
cancer is trastuzumab, a monoclonal antibody directed against the human 
epidermal growth factor receptor-2 (HER2). Targeting growth factor receptors 
have be proved to be effective. However, since HER2 is only expressed in a 
subpopulation of breast cancer, other tumor types lacking HER2 expression do 
not benefit from this therapy. Thus, there is a need to explore other targets and 
growth factor pathways.  
The IGF system   
 The insulin-like growth factor (IGF) family, which consists of multiple 
receptors, extracellular ligands (IGF-I, IGF-II, insulin) and binding proteins 
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(IGFBPs 1-6), belongs to the receptor tyrosine kinase superfamily and has been 
implicated in tumorigenesis and malignant phenotypes. There are at least five 
different types of receptors in the system, including the type I IGF receptor 
(IGF1R), insulin receptor (InsR), IGF1R/InsR hybrid receptor, insulin-receptor-
related receptor (IRR) and the type II IGF receptor (IGF2R).  
 Unlike sother receptor members of the IGF family, IGF1R and InsR have 
been extensively studied for decades. They are dimeric receptors and share 45-
65% similarity in ligand-binding domains and 84% in the catalytic domains [4, 5]. 
Each monomer is synthesized as a heavily glycosylated single chain proreceptor 
and proteolytically cleaved to yield α and β subunits with molecular weights of 
around 135 kDa and 90 kDa, respectively [6]. The α subunit contains 
extracellular ligand binding sites; while the transmembrane β subunit contains the 
intracellular tyrosine kinase domain. Two αβ subunits are then covalently linked 
by disulfide bonds to form either a holo-receptor, which is composed of two 
identical monomers, or a heterodimer, which is made of a single chain of InsR 
and a single chain of IGF1R. The heterodimer is also known as IGF1R/InsR 
hybrid receptor. InsR exists in two isoforms: Isoform A and B due to alternative 
splicing of exon 11. As a result, InsR-A, lacking exon 11 is 12 amino acids 
shorter than InsR-B. InsR-B tends to be a metabolic receptor and is mainly 
expressed in adult muscle, liver and fat; whereas InsR-A is predominantly 
expressed during fetal development and in cancers. 
  IRR was first discovered due to its high homology to family members [7]. 
However, IRR is an orphan receptor as no endogenous ligand has been 
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identified despite efforts including the whole genome search for substances with 
high sequence similarity to insulin or IGFs [7-9]. It is mainly expressed in the 
kidney and has only been described as an alkali sensor and regulator in the body 
[10]. On the other hand, IGF2R, which is also known as cation-independent 
mannose-6-phosphate receptor lacks tyrosine kinase activity and signal 
transduction capability [11]. Studies have shown its important functions in 
multiple cellular pathways and that loss of IGF2R is associated with progression 
of tumorigenesis. One of its roles is facilitating the activation of latent TGF-β by 
inducing G1 arrest in cancer cells [12-14]. IGF2R also acts as a sequester for 
many extracellular ligands such as IGF-II [15, 16]. When IGF2R expression is 
low, IGF-II bioavailability increases and therefore promotes IGF-II signaling via 
IGF1R. Thus, the field has also referred IGF2R as a IGF-II “sink” and may be a 
potential tumor suppressor. Due to its multiple functions in cellular processes, 
IGF2R’s role in breast tumor is not fully understood.    
 Three known ligands IGF-I, IGF-II and insulin bind to their receptors with 
different binding affinity and specificity. At physiological concentrations, IGF-I 
binds solely to IGF1R; IGF-II binds to IGF1R and InsR-A; while insulin binds to 
InsR with higher affinity for InsR-A. However, in certain circumstances in such 
that IGF-I is at much higher concentration than the preferential ligand insulin, 
IGF-I can bind to InsR. Similar situation can also apply to insulin and IGF1R. The 
affinities of IGF1R and InsR for their ligands are as following: InsR, insulin >> 
IGF-II > IGF-I; IGF1R, IGF-I > IGF-II >> insulin; IGF2R, IGF-II > IGF-I (insulin 
does not bind). Upon ligand binding, the receptors undergo autophosphorylation 
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within the tyrosine kinase domain and subsequently initiate signal transduction 
pathways. A number of adaptor proteins, such as insulin receptor substrates 
(IRS-1, IRS-2), Grb2 and Shc are recruited to the membrane. These events then 
trigger various downstream signaling cascades including mitogen activated 
protein kinase (MAPK) and phosphatidylinositol-3 kinase (PI3K). These pathways 
regulate a wide array of transcription factors and gene expressions, ultimately 
resulting in protein synthesis, cell growth, proliferation, metabolism and survival 
[17, 18].  
. IGF-I and IGF-II are single-chain polypeptides of about 7.5 kDa and are 
highly homologous, sharing 70% sequence similarity and 50% homology to 
proinsulin [19]. Despite their high homology, these ligands have very different 
origins. IGF-I and IGF-II are mainly produced in hepatocytes under the control of 
growth hormone (with much lesser degree for IGF-II) and circulated in the blood 
at 20-80 nM concentrations. Under normal condition, hypothalamus releases 
growth-hormone-releasing hormone and somatostatin to regulate the production 
of growth hormone (GH) in pituitary. Once GH is released, it binds to GH 
receptor in the liver, which in turn stimulates the production of IGF-I in an 
endocrine fashion. Circulating IGF-I acts on the negative feedback loop of 
GH/IGF-I axis and maintains their physiological serum concentrations [20]. In 
addition, IGF-I and IGF-II can also expressed in target tissues such as kidney, 
skeletal muscle, spleen, brain and heart, suggesting that they can also act 
through autocrine and paracrine manners [21-23]. IGF-I plays critical roles in 
skeletal muscled physiology and the change in IGF-I level at different stages of 
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life is particularly responsible for the pubertal growth spurt. IGF-I level is low at 
birth; it starts to increment in the childhood and peaks during puberty, reaching 
around 2-3 folds more than adult level [24, 25].  
 In contrast, IGF-II level does not change with age. It is preferentially 
expressed in early embryonic and fetal development. It may substitute for IGF-I 
when IGF-I level is low, however not much is known about IGF-II’s physiological 
functions in adulthood. Most studies have implicated its roles in early stages of 
carcinogenesis and a variety of tumors growth; some evidence has shown that 
IGF-II local expression contributes to metabolic syndrome, abnormalities in 
cardiac architecture (enlarged left ventricle, bradycardia) and atherosclerotic 
lesions [26-28].  
 Mature insulin, which consists of two polypeptides chains A and B linked 
by disulfide bonds has a molecular weight of about 5.8 kDa. It is first produced by 
pancreatic β-cells as a pre-proinsulin and is processed into proinsulin in rough 
endoplasmic reticulum and Golgi, respectively. Its activation is preceded by the 
cleavage of C-peptide. Unlike IGFs, insulin production, excretion and activity are 
not influenced by GH [24, 29]. Insulin mainly affects metabolism of hepatocytes, 
myocytes and adipose tissue cells. However, a number of studies including our 
group have shown that insulin’s effect is not limited to glucose homeostasis. 
Insulin can also drive mitogenicity.  
 Six IGF binding proteins (IGFBPs) have been identified, sharing 
conserved protein structure and high binding affinity for IGF-I and IGF-II. Thus, 
they are characterized as modulators of IGF bioavailability, signaling and activity 
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[30, 31]. However, their functions remain controversial. They are six distinct 
proteins with each having evolved with exclusive functions and properties [32]. 
IGFBP-3 is the most abundant IGFBP in the circulation. It binds to about 90% of 
the IGFs and has an affinity of about one order magnitude higher than that of 
IGF1R [33]. Many studies have examined the relationship between circulating 
IGFBP-3 level and cancer risk or prognosis, no consistent evidence has been 
found [34-38]. Although IGFBP-3 may act as a IGF-I suppressor by diminishing 
their bioavailability to IGF1R, some discussion indicated that IGFBP-3 stabilizes 
IGF-I in the binary or tertiary complex and facilitates IGF transport through body 
compartment [39]. In contrast, IGFBP-1 and IGFBP-2 mainly involve in diet and 
metabolic balance [40, 41]. While IGFBP-3 is positively regulated by GH, both 
IGFBP-1 and IGFBP-2 are suppressed by GH and further decreased by insulin 
secretion. Patients with chronic hyperinsulinemia or obesity are associated with 
lower IGFBP-1 and IGFBP-2 [41].  Studies suggested that the inversely 
relationship between IGFBP-1/IGFBP-2 and insulin in a hyperinsulinemic 
condition increases free-IGF and favors IGF activity. However, circulating IGFBP-
1 and IGFBP-2 alone are not associated with cancer risks [42, 43]. On the other 
hand, IGFBPs 4-6 do not seem to play critical roles in regulating endocrine IGFs. 
They have been shown to exhibit IGF-independent actions and may be regulated 
in a cell-specific manner. At present, there is no clinical indication for measuring 
these binding proteins [44].  
ER system and hormonal therapy in breast cancer 
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 Estrogen receptor (ER) belongs to the nuclear receptor superfamily and 
functions as a transcription factor for a number of target genes [45]. Binding to its 
ligand – estrogen, which is a natural steroid hormone – allows ER to regulate 
various physiological processes in a broad range of target tissue in human body, 
including breast, genital tract, cardiovascular, bone and brain [46].  
 There are two forms of ER: ERα and ERβ, which are encoded by genes 
ESR1 (chromosome 6) and ESR2 (chromosome 14), respectively [47]. Both ERα 
and ERβ are composed of 6 domains termed A to F from N- to C-terminus. 
Domain AB, which is also known as activation function (AF-1) is a ligand-
independent region that involves transcriptional activation and protein-protein 
interaction with other transcription factors. Domain C is the DNA-binding domain 
(DBD), containing two zinc finger motifs; while the domain D is the hinge, serving 
as the rotational site for conformational alteration of the receptor. Domain E is the 
ligand-binding domain (LBD) that allows homo- or hetero- dimerization upon 
ligand binding. This LBD also harbors activation function 2 (AF-2), where its 
transcriptional activation function including conformational change of the receptor 
is dependent on ligand binding. Both AF-1 and AF-2 are the important domains 
that influence transcriptional activity of the ERs. They recruit a range of co-
regulatory protein complexes to assist transcriptional activation of target-gene 
expression [48, 49]. Domain F is still poorly understood. ERα and ERβ display 
high conservation, approximately 97% in the DBD but considerably less 
conservation, approximately 59% in the LBD (Figure 1.1). This suggests that they 
10 
 
interact with similar estrogen response element (ERE) sequences but may have 
different ligand-binding characteristics [49].  
 After many years of extensive research on estrogen and ER, it has 
become clear about the contribution of ER in breast cancer development. 
Estrogen was never suspected as a carcinogen until about decades ago, when it 
was discovered as a key growth factor for driving breast carcinoma and 
contributed to the majority of the breast cancer cases. (Estrogen was added into 
the carcinogen list in 2002 by National Institute of Environmental Health 
Science.) ER has become the major prognostic and therapeutic determinant in 
the breast cancer clinic. About 75% of the breast cancer patients are estrogen 
receptor positive (ER+). This is usually referred to high ERα expression in the 
breast tumors. ERα is only expressed in small percentage (7-10%) in normal 
breast tissues, in contrast to ERβ expression that is relatively high (80-85%) [50-
52].  Studies demonstrated during tumor progression, ERα expression level rose, 
while ERβ expression level decreased [53]. Overexpression of recombinant ERβ 
inhibited ERα-induced transcription [54, 55], proliferation [56, 57], migration [58] 
and sensitized cells to tamoxifen [59], indicating that ERβ may serve as a tumor 
suppressor. However, some studies have shown ERβ expression was associated 
with high proliferation (Ki67 expression) and high tumor grade [53, 60]. The 
interplay between ERα and ERβ has become more complicated and the 
definitive role of ERβ in breast carcinogenesis is still elusive.  
 Blocking ER pathway has proven beneficial in neoadjuvant, adjuvant and 
metastatic settings [61-63]. There are three major classes of anti-estrogen 
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agents with different targeting mechanisms of action. 1.) selective estrogen 
receptor modulators (SERMs), 2.) estrogen receptor down regulators (SERDs), 
and 3.) aromatase inhibitors (AIs). SERMs such as tamoxifen prevent the binding 
of estrogen to ERs by blocking the recruitment of co-activators to AF-2 but not 
AF-1, thus blocking the activation of nuclear ERs. Since AF-1 remains open, 
partial estrogen agonist activity in skeletal, cardiovascular, central nervous 
system and gastrointestinal tract is expected [64]. Unlike SERMs, SERDs such 
as fulvestrant, is a pure antiestrogen with no agonist activity. Binding of 
fulvestrant to ERs impairs receptor dimerization, blocks nuclear localization of the 
receptor, blocks the transcriptional activation of AF-1 and AF-2 and subsequently 
promotes ER degradation. The ability of SERDs to reduce cellular ER level 
suggests its better efficacy compared to that of tamoxifen in postmenopausal 
women with breast cancer [65]. On the other hand, AIs such as letrozole, 
anastrozole and exemestane do not interact with ERs, but rather, interfere the 
conversion of androgen into estrogen. Moreover, they also lack estrogen agonist 
activity, providing a rational for the development of AIs as an alternative therapy 
to tamoxifen [66].  
Crosstalk between ER and IGF systems 
 Estrogen functions through two distinct signaling: ligand-dependent 
genomic and ligand-independent non-genomic pathways. In the genomic 
pathway, estrogen diffuses into the cell and bind ER, which is located in the 
nucleus. Once activated, ERs dimerize and bind to specific response elements 
known as estrogen response elements (EREs) in the promoter of target genes. 
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Estrogen binding, in this case induces a conformational change in the receptors, 
allowing the release of co-repressors and recruitment of co-activators such as 
AIB1 and ARC1 to the appropriate sites. Direct binding of activated ER to ERE is 
referred as the classical genomic pathway. However, ER regulated gene 
expressions do not solely rely on this classical mechanism. Around one third of 
the genes in humans that are regulated by ERs do not contain ERE-like 
sequences. ER can also indirectly associate with promoters of target genes 
through protein-protein interactions with other DNA-binding transcription factors 
such as AP-1, SP-1 and NF-kB, in an ERE-independent manner [67-69]. In this 
non-classical genomic pathway, ER, acting as a co-activator regulates the 
transcription of target genes that lack ERE but have a binding element for its 
tethered transcription proteins. 
 In addition to the genomic pathway, estrogen can also mediate signal 
transduction pathway through plasma membrane. Evidence has shown the 
presence of ERs at the plasma membrane and they are responsible for 
extranuclear, rapid and non-genomic actions [70-72]. Non-genomic actions are 
frequently associated with the activation of various protein-kinase cascades such 
as adenylate cyclase, phospholipase C, MAPK/ERK and PI3K/AKT pathways 
[73]. Thereby, membrane ERs potentially associate with many growth factor 
receptors such as IGF1R, EGFR and contribute to a variety of cell proliferation, 
differentiation and metabolic functions [67, 74].  
 The cross-talk between ERα and IGF pathway is well-established and 
occurs bidirectional. Estrogen influences the IGF system at multiple levels by 
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sensitizing the IGF system. Estrogen increases the expression of both IGF1R 
and IRS-1 in breast cancer cells, resulting in enhanced IGF signaling and 
activation of downstream pathways such as ERK and AKT [75]. Total and 
phosphorylated IRS-1 is upregulated with estrogen in MCF-7L xenografts. 
Removal of estrogen halted tumor growth and decreased IRS-1 expression [75]. 
Estrogen increases IGF-II secretion and affects breast cancer in an autocrine 
manner [76]. Furthermore, estrogen decreases IGFBP-3 expression, an IGF 
ligand sequester; while a pure antiestrogen, ICI-182780 increases IGFBP-3 level 
in breast cancer cells [77]. Reciprocally, IGF-I activates ER-mediated signaling in 
a ligand-independent manner [78-80], particularly through the phosphorylation of 
ER at both Serine 118 and Serine 167 residues [81, 82]. IGF-I induces ERα 
expression, increases phosphorylation of co-activators and other regulatory 
proteins of ERα activity [79, 80, 83] and potentiates ERα transcriptional activity 
by increasing the expression of ERα target genes, e.g. progesterone receptor 
[84]. When recombinant IGFBP-1 was used as an inhibitor for IGF-I action, it 
abolished IGF-I-dependent ERα activity and growth in breast cancer cells [85]. 
Reduced serum IGF-I was also observed in patients treated with tamoxifen [86, 
87].    
 Estrogen was originally believed to exert its proliferative effects through 
direct activation of gene expression (via genomic action). Evidence has 
suggested many of these estrogen-responsive genes are key components of 
growth factor pathways (including the IGF pathway), which in turn, not only 
contribute to the already existing proliferation matters, but can also directly 
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reactivate the ER pathway. The synergistic relationship of ER and growth factors 
intensifies the growth-promoting environment in breast cancer and also adds 
another level of complexity to the treatments of breast cancer, suggesting that 
multiple level of inhibitions may be necessary.  
Targeting IGF system 
 In addition to the crosstalk of IGF1R with ER pathway, IGF system itself 
has also been implicated in different types of malignancies, including breast 
cancer [88-91]. Activation of IGF1R stimulates cell proliferation [92, 93], 
enhances survival [93, 94], regulates cell metabolism [95] and promotes 
metastasis [94, 96]. Collective evidence has shown that blocking IGF system 
inhibits growth and metastasis in vitro and in vivo [97, 98]. Multiple strategies 
targeting IGF system have been developed and tested in the clinical trials as 
shown below.  
Neutralization of IGF-I and IGF-II ligands 
 MEDI-573 (MedImmune) is a dual-specific neutralizing antibody against 
IGF-I and IGF-II ligands. Several pre-clinical studies have shown efficacy in 
blocking IGF-driven cell proliferation in vitro [99], tumor growth [100, 101] and 
angiogenesis [99] in sarcoma xenografts in vivo. Combination of MEDI-573 with 
either mTOR inhibitor (rapamycin and AZD2014) [101] or anti-IGF1R (MAB391) 
[99] were more effective in blocking tumor growth. In phase I dose-escalation 
study, MEDI-573 was well tolerated with no notable perturbation in metabolic 
homeostasis and preliminary anti-tumor activity has also been observed 
(NCT00816361 and NCT01340040). A phase II clinical trial of MEDI-573 testing 
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in patients with hormone-sensitive metastatic breast cancer is underway 
(NCT01446159).  
 BI-836845 (Boehringer Ingelheim ) is another IGF-I/IGF-II neutralizing 
antibody. Most of the studies are still in phase I trials testing patients with various 
solid tumors. One of them is a phase I/II study of BI-836845 in combination with 
exemestane (aromatase inhibitor) and everolimus (mTOR inhibitor) testing in 
ER+/HER2- advanced breast cancer patients (NCT02123823).  
Targeting downstream IGF/insulin receptors 
 AKT/PI3K/mTOR is one of the main downstream networks of receptor 
activation. Around 40% of ER+, 23% HER-positive and 8% basal-like breast 
tumors present PIK3CA mutations [102]. TP53 mutation, however is much more 
prevalent in basal-like (84%) and HER2-positive (75%) compared to luminal 
(22%) breast tumors. AKT1 and PTEN mutations have also been reported, but 
they are relative less frequent in breast cancer [103]. Few AKT inhibitors have 
made their way to clinical evaluation. Ipatasertib (GDC-0068, Genentech), an 
ATP-competitive AKT inhibitor demonstrates safety profile and disease control in 
a subgroup of patients in a phase I study testing patients with solid tumors [104].  
AZD-5363 (AstraZeneca) and Afuresertib (GSK2110183, Novartis) are being 
evaluated in phase II trials, including an ongoing study testing patients with 
invasive ER+ breast cancer (NCT02077569).   
 Mammalian target of rapamycin (mTOR) is a serine/threonine protein 
kinase located downstream of PI3K/AKT signaling cascade. It has appeared to 
be a favorable alternative target for cases with PIK3CA mutations since a 
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downstream blockage is able to fully suppress the aberrant PI3K/AKT activation 
due to the mutation. This is less likely with an upstream inhibition. However, 
some caution is warranted in using mTOR inhibitors. mTOR in conjunction with 
ribosomal protein S6 kinase (S6K), which is one of mTOR downstream 
molecules, mediate negative feedback of PI3K/AKT action by inhibiting IRS-1 
function. The phosphorylation of IRS-1 at multiple residues, including serine 
636/696 by mTOR and serine 270/307/636/1001 by S6K promotes IRS-1 
degradation [105] and subsequently AKT inhibition. This negative feedback loop 
of mTOR is disrupted with mTOR suppression. A combination treatment of 
mTOR inhibitor with PI3K or IRS-1 inhibitors may be an option. Dual-specific 
PI3K/mTOR inhibitor, such as NVP-BEZ235 are in preclinical and clinical studies 
although some toxicities have been reported. Currently, there are two mTOR 
inhibitors approved for use in treating cancer in the United States: everolimus 
(Novartis) and temsirolimus (Pfizer). Ridaforolimus (Merck) has recently been 
dispproved.by the FDA. Everolimus combined with an AI improved progression-
free survival in patient with ER+ advanced breast cancer who have progressed 
on nonsteroidal AI in the phase III trials and this regime has incorporated into 
clinical practice [106, 107].  
 Cyclin-dependent kinases 4 and 6 (CDK4/6) are protein kinases in cell 
cycle regulating DNA replication and cell division. The cell cycle is divided into 
phases: G0 (quiescence), G1 (pre-DNA synthesis), S (DNA synthesis), G2 (pre-
division), and M (cell division). The progression from G1 to S is a critical 
checkpoint in protecting the cell from abnormal replication, and that process is 
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tightly regulated by CDK4/6 and cyclin D, the expression of which is controlled by 
IGF/insulin [108]. Palbociclib (Pfizer), a CDK4/6 inhibitor is approved in 2015 for 
use in treating postmenopausal women with metastatic breast cancer who are 
resistant to endocrine treatments [109]. A phase III clinical trial of Palbociclib has 
shown efficacy in combination with fulvestrant in women with ER+/HER- 
advanced metastatic breast cancer [110].  
 Another major downstream network of IGF/insulin receptor activation is 
Ras/Raf/MEK/ERK pathway. Alterations of this pathway, including mutations and 
upregulation of MAPKs have been well documented in many cancers. Genes 
MAP3K1 and MAP2K4 are one of the highest mutated genes in breast cancer 
after PIK3CA and TP53 [103], resulting in upregulation or constitutive activation 
of MAPK pathway. This is particularly observed in the basal-like/triple-negative 
breast cancer cells. U0126 is an example of selective inhibitor of MEK1/2 that 
lacks pharmaceutic properties for clinical evaluation. However, it is an invaluable 
research tool for dissecting the MEK/ERK pathway. The status of additional 
approaches and targets of this signaling pathway that are under preclinical and 
clinical evaluations are described in this article [111].  
 Other potential downstream interventions include S6K inhibitor, H89 [112] 
and IRS-1 inhibitor, NT157 [113]. They did not receive as much attention 
compared to other targets, however few investigators, including our group have 
shown some interesting outcomes with these inhibitors.      
Blockage of receptor activation 
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 Past years, IGF1R has been the central focus of IGF interference. Many 
humanized monoclonal antibodies have been designed and developed to bind 
specifically to IGF1R, and not InsR. This class of drugs interferes the binding of 
ligands to the receptors by triggering receptor endocytosis and subsequently its 
degradation in the endosome [114]. Few examples of these antibodies are 
Figitumumab (Pfizer), Dalotuzumab (Merck), cixutumumab (Imclone) and 
Ganitumab (Amgen) [17]. They have been evaluated in clinical trials, either as 
single agents or in combination with other antitumor drugs in various cancers. 
Unfortunately, these trials have shown no benefit in the tested patients in late-
phase clinical trials. Substantial toxicities, including elevated GH and circulating 
IGF-I levels, hyperglycemia and hyperinsulinemia have been reported [115-117]. 
The anti-IGF1R monoclonal antibodies disrupt the negative feedback control of 
endocrine IGF-I as the brain fails to detect IGF-I levels. This results in an 
increase in serum GH and IGF-I production by liver. The elevated GH also 
induces insulin resistance, probably due to increased lipolysis and free fatty acid 
production from the liver, thus resulting in elevated insulin production by 
pancreas [20]. The enhanced levels of GH, IGF-I and insulin from anti-IGF1R 
monoclonal antibodies might activate InsR unwantedly. Since anti-IGF1R 
monoclonal antibodies do not block InsR, this may be a concern. InsR could 
certainly drive survival and compensatory signaling and blunt the therapeutic 
effects of anti-IGF1R monoclonal antibodies.  
 The reasons why we did not see the effects of monoclonal antibodies on 
the endocrine systems in the preclinical animal models is due to the substantial 
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difference between human and murine endocrine systems [118]. Mice have low 
circulating levels of IGF-II postnatally; while humans have high levels of IGF-II 
[119]. Besides, these monoclonal antibodies are developed specifically against 
human IGF1R and thus have minimal effects on murine IGF1R. Although 
blocking the IGF1R with monoclonal antibodies has shown tumor inhibition in 
mice, mouse model does not fully recapitulate a human system, and thus it is not 
a perfect model for studying the effects of endocrine disruptors like IGF1R 
inhibitors. Another explanation for the failure of the anti-IGF1R monoclonal 
antibody trials could be the lack of molecular biomarkers to predict the benefits 
from anti-IGF1R treatments [118]. An exploratory analysis of serum biomarkers 
suggested that elevated levels of IGFs and IGFBP may potentially be predictive 
markers for anti-IGF1R treatment, however later trials could not confirm this 
observation and found no correlation between levels of IGF-I, IGFBP-2 and 
IGFBP-3 with the treatment of anti-IGF1R monoclonal antibody. IGF1R mRNA 
expression, cell surface expression, copy number and mutation status were not 
associated with tumor responsiveness to IGF1R inhibition in osteosarcoma [120]. 
Perhaps, other biomarkers outside of serum IGF-I and IGF1R expression levels 
need to be exploited. 
 Other than antibodies, IGF1R activation can also be blocked by tyrosine 
kinase inhibitors (TKIs), which are small molecules competing for the ATP 
binding site in the catalytic domain of the β subunit of the receptors. Most of the 
drugs of this class originally aimed to target IGF1R’s ATP binding site. Due to 
high homology of the catalytic domains between IGF1R and InsR, these TKIs 
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lack IGF1R selectivity and exhibit some inhibitory effects on InsR. BMS-754807 
(Bristol-Myers Squibb) and linsitinib (OSI-906, OSI Pharmaceuticals) are two 
examples of TKIs, targeting both IGF1R and InsR. They have shown efficacy in 
blocking tumor growth in vitro and in vivo. Combination studies with either 
chemotherapy, hormonal or targeted agents have shown synergistic benefits 
[121-123]. Phase I/II studies of OSI-906 showed safety profile, but failed to show 
anti-tumor activity in unselected relapsed non-small-cell lung cancer patients 
[124, 125]. So far, no result of the clinical trials testing BMS-754807 has been 
released.  
Roles of InsR in breast cancer  
 While InsR is often thought to associate with blood sugar management 
and diabetic condition, it is also a key growth regulatory factor that can stimulate 
mitogenic phenotypes similarly to IGF1R. Insulin has been long considered 
essential for the growth and development of rodent mammary [126]. Studies 
looking into the roles of insulin and InsR in cancer have been conducted as early 
as in the 1970s. Insulin administration influenced mammary tumor growth 
induced by a carcinogen, 7,12-dimethylbenz(a)anthracene (DMBA) [127] and the 
mammary tumor regression was observed when the rats were given alloxan 
diabetes to destroy tumor pancreatic β-cells, resulting in insulin deficiency [128]. 
In a non-obese mouse model of type II diabetes, insulin accelerates breast 
cancer development and progression [129]. Furthermore, our lab has shown that 
down-regulation of InsR in breast cancer cells and xenografts caused reduced 
proliferation, angiogenesis, angiogenesis and lymphangiogenesis [130].  
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 In addition to the data from animal studies, elevated InsR levels are 
detected on human breast, colon, kidney, lung, ovary and thyroid carcinomas 
[131]. In breast cancer specifically, approximately 80% of the samples have an 
IR content 2-20 fold higher than normal breast tissues [132]. Human disease 
states such as type II diabetes and obesity, which are often accompanied by 
hyperinsulinemia, are associated with an increased risk for many cancer types, 
including breast cancer. Breast cancer patients with high insulin levels are much 
more likely to suffer from metastasis, disease recurrence and reduced survival. 
The effects of hyperinsulinemia in human are thought to be cancer-promoting 
due to elevated circulating level of insulin, chronic exposure of insulin on 
peripheral tissues and reduced insulin sensitivity of the pancreas to regulate 
glucose levels, which may lead to hyperglycemia and low grade inflammation 
[133]. Higher glucose consumption by cancer cells, in contrast to nonmalignant 
cells, has been well observed and recorded. Most cancer cells have altered 
metabolism and predominantly produce energy through the fermentation of 
glucose to lactate regardless of oxygen availability (Warburg effect) [134]. 
Therefore, hyperinsulinemia can reinforce the permissive role of sufficient energy 
substrate availability by cancer cells and is recognized as an underlying cause of 
cancer. 
 Cumulative evidence of clinical and epidemiological studies suggests that 
insulin and InsR involve in the formation and maintenance of malignant 
phenotypes. The levels and phosphorylation of InsR are associated with poor 
survival in breast cancer [135, 136]. Overexpression of InsR also predicts a poor 
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survival among patients with non-small-cell lung cancer [137]. Although a study 
suggested differently that high InsR expression is an independent predictor of a 
favorable clinical outcomes in early stage breast cancer, the IGF-II levels were 
significantly higher in patients with low tumor InsR expression, suggesting that 
ligand levels may also affect the clinical outcomes independent of the receptor 
levels [138]. They also mentioned the lack of sensitive quantitative assessment in 
the study that might not pick up the effects of down-regulation of InsR. No doubt, 
the InsR role in cancer is established and may be an important implication 
considering that the clinical trials of IGF1R blocking antibodies are not efficient in 
controlling tumor growth in the tested patients. Targeting both IGF1R and InsR 
may be a better choice for cancer therapy. However, the biological response of 
insulin on cancer cell proliferation and invasiveness cannot be predicted solely 
based on the insulin content [139]. The prognostic value of InsR inhibition in the 
clinical setting of human malignancies needs to be defined. 
Rationale and purpose of this study 
 Generation of endocrine resistant breast cancer models demonstrated the 
lack of IGF1R expression and inefficacy of IGF1R inhibition. InsR, which is a 
closely related receptor of IGF1R remains intact and functional in these models. 
The purpose of the study is to understand how InsR influences the development 
of endocrine resistance. The work is to determine the role of InsR in endocrine 
resistant breast cancer model, to evaluate the efficacy of InsR inhibition in human 
breast cancer, and to develop and characterize small molecular agents of InsR 
for therapeutic purposes. 
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Hypothesis 
 InsR serves as a compensatory pathway to IGF1F and InsR inhibition is 
necessary to overcome acquired resistance breast cancer to endocrine therapy.   
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Figure 1.1. Comparison of primary structure between ERα and ERβ. They 
are composed of 6 domains labelled from A to F from N- to C-terminus. Degree 
of homology of each domain between the two ER isoforms is represented as 
percentage. 
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Figure 1.2. Schematic diagram of IGF family. IGF-I and IGF-II and insulin are 
natural ligands of transmembrane tetrameric receptors: IGF1R, InsR and hybrid 
receptors. The bioavailability of IGF-I and IGF-II are regulated by IGFBPs. Upon 
ligand binding, activated and phosphorylated receptors recruit a number of 
adaptor proteins and activate two major pathways: PI3K/AK and MAPK/ERK 
pathways. Uncontrolled activation of these receptors in cancer result in aberrant 
proliferative phenotypes.   
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Targeting insulin receptor in human breast cancer, 
particularly in endocrine-resistant breast cancer  
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Introduction 
 Approximately 75% of the breast cancer cases express estrogen receptor-
α, representing the most prevalent breast cancer subtype [140]. Patients with 
ER-positive breast cancer can be treated by inhibiting ER function. This strategy 
has been successful in early stage and advanced breast cancer [61, 62], but a 
significant proportion of patients never responded to ER inhibition (de novo or 
primary resistance) or have progression after a prolonged period of therapy 
(acquired or secondary resistance) [141, 142]. Endocrine resistance still poses a 
key clinical problem. Recently, targeting of mTORC1 and CDK4/6 have been 
used to treat ER-positive tumors [143, 144], but there is still a need for additional 
strategies, aiming to delay or ideally overcome resistance to endocrine therapy. 
This system has been implicated in cancer development as well as 
crosstalk with ER, suggesting that it may contribute to the regulation of ER-
positive breast cancer [145, 146]. IGF1R is an estrogen regulated gene and 
enhances ER transcriptional activity, suggesting co-targeting of ER and IGF1R 
might be clinical useful [84, 147]. A number of anti-IGF inhibitors including anti-
IGF1R mAbs, TKIs and ligand neutralizing antibodies were developed primarily 
to target IGF1R and IGF ligands while leaving InsR unperturbed [118]. Despite 
the hope that anti-IGF1R targeted therapies would provide clinical benefit in 
endocrine resistant breast cancer, we showed that TamR cells lacked IGF1R 
expression [148]. This finding was validated in women with breast cancers – 
recurrent endocrine treated tumors showed lower level of IGF1R compared to the 
pre-treated tumors [149, 150]. Thus, it would be unlikely for anti-IGF1R mAbs to 
have clinical activity in endocrine resistant cells. These observations likely 
28 
 
explain why the results of phase III clinical trials of anti-IGF1R mAbs tested in 
endocrine resistant population have been negative [151].  
Unlike IGF1R, InsR is not an estrogen regulated gene and its level 
remained intact in TamR cells. InsR is closely related to IGF1R, sharing 84% 
similarity within catalytic domain, 45-65% in ligand-binding domain and more 
than 50% in the overall amino acid sequence [6]. The highly homologous InsR 
activates almost identical downstream signaling cascades in a ligand-dependent 
fashion. On the loss of IGF1R function, osteoblasts shifted from IGF- to insulin-
mediated growth and differentiation [152]. Down-regulation of IGF1R in breast 
cancer increased sensitivity to insulin [153]. In addition, a patient tumor 
developed an increased InsR gene copy number while being treated with, and 
eventually becoming resistant to endocrine therapy [154]. Although InsR 
expression in cancer has been documented for several decades [130-132, 155], 
InsR inhibition has been intentionally avoided because of concern over disrupting 
glucose homeostasis.  
InsR inhibitors have been developed as dual IGF1R/InsR tyrosine kinase 
inhibitors: BMS-754807 and OSI-906. These two drugs have completed several 
clinical trials, including a phase II study against ER+ breast cancer resistant to 
aromatase inhibitors. The trial has completed but the results have not been 
disclosed (NCT01225172). Early clinical evidence suggests that TKIs are safer 
than originally anticipated. Although hyperglycemia was evident in patients 
treated with OSI-906, encouraging disease control was observed in patients 
[156, 157].  
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In this study, we determined that InsR signaling serves as a bypass 
pathway and compensates for the loss of IGF1R in TamR breast cancer cells. 
We suppressed InsR functions using three different mechanisms in TamR versus 
parental breast cancer cells. Our data showed that InsR inhibition alone blocked 
signaling and cell proliferation in TamR cells but not in the parental cells. When 
anti-IGF1R mAb was given in conjunction with S961 or shIR, a complete 
suppression of insulin-stimulated growth in endocrine-sensitive parental breast 
cancer cells was observed. An additive down-regulation of receptor levels and a 
synergistic blockage of ligand-mediated signaling using combination treatments 
of anti-IGF1R and anti-InsR mAbs were also observed in a triple negative breast 
cancer cells, suggesting the involvement of hybrid receptors in the mediation of 
IGF/insulin in breast cancer cells. Thus, dual inhibition of IGF1R and InsR is 
necessary for optimal suppression of this signaling system. 
Results 
TamR cells were more sensitive to insulin compared to their parental cells 
MCF-7L and T47D are ER-positive human breast cancer cell lines and are 
estrogen sensitive and can be inhibited by SERMs such as tamoxifen. We 
previously generated TamR cells from MCF-7L and T47D and showed reduced 
IGF1R expression levels and a lack of efficacy of anti-IGF1R monoclonal 
antibodies in TamR cells. However, AEW541, a dual TKI that targets both IGF1R 
and InsR was able to inhibit insulin- and IGF-stimulated signaling and growth 
[148].  
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To better understand the role of insulin/InsR in TamR cells, we treated 
MCF-7L, T47D and their TamR cells with increasing concentrations of insulin for 
15 minutes. As measured by AKT, P70S6K and MAPK phosphorylation, insulin 
signaling stimulated phosphorylation at lower levels of insulin in TamR cells 
compared to MCF-7L or T47D parental cells (Figure 2.1). Monolayer growth and 
soft agar assays showed greater proliferation (Figure 2.2) and colony formation 
(Figure 2.3) at lower concentrations of insulin in TamR cells compared to their 
parental cells.  
Genetic knockdown of InsR reduced insulin-regulated signaling and growth in 
TamR cells, but not in the parental cells. 
Stable InsR knockdown cell lines were generated in MCF-7L, T47D and 
their TamR cells using lentiviral shRNA. IGF1R level was unaffected in both 
MCF-7L and T47D parental cells. Compared to control shRNA, shIR#6 was a 
more efficient knockdown construct than shIR#2 as down-regulations of InsR 
protein and mRNA levels were greater in cells transduced with shIR#6, validated 
by immunoblotting (Figure 2.4) and qRT-PCR (Figure 2.5). A reduction of insulin-
mediated signaling was measured by IGF1R/InsR, AKT, MAPK, P70S6K and 
IRS (pY-20) phosphorylation after InsR knockdown in TamR cells especially in 
shIR#6 TamR cells. Surprisingly, this was not the case in parental cells even 
though the InsR level was significantly down-regulated (Figure 2.4).  
To further examine if InsR knockdown affected biological functions, cells 
were studied by cell cycle analyses, monolayer growth, and anchorage-
independent growth assays. Down-regulation of InsR abolished insulin-mediated 
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proliferation (Figure 2.6), cell cycle progression (Figure 2.7) and anchorage-
independent growth (Figure 2.8) in MCF-7L and T47D TamR cells, but not in 
MCF-7L or T47D parental cells. Re-introduction of recombinant human InsR 
(hIR) in shIR#2 and shIR#6 transduced MCF-7L TamR cells rescued insulin-
mediated signaling (Figure 2.9) and cell proliferation (Figure 2.10).  
In contrast, InsR overexpression in both MCF-7L and TamR cells showed 
a mild up-regulation of InsR protein level and also insulin-mediated 
phosphorylation of IRS (pY-20), AKT, P70S6K and MAPK (Figure 2.11A). 
However, only MCF-7L TamR cells showed a significant increase in cell 
proliferation (Figure 2.11B).  
S961 inhibited insulin-regulated PI3K/MAPK signaling and growth in TamR cells, 
but not in parental cells.  
S961, a small peptide was synthesized and shown to be a competitive 
antagonist with a slightly higher affinity to InsR than insulin and partial agonist 
effects at lower concentrations [158]. S961 has very low affinity for IGF1R.  To 
examine the effect of S961 in endocrine resistance cells, cells were pre-treated 
with increasing concentrations of S961 before exposing cells to either IGF-I or 
insulin. S961 did not inhibit IGF-I or insulin-regulated signaling in MCF-7L and 
T47D parental cells even at high concentration as shown by IGF1R/InsR, AKT 
and MAPK phosphorylation (Figure 2.12A and 2.13A). Similarly, S961 did not 
inhibit insulin or IGF-I stimulated cell cycle progression (Figure 2.14A and 2.15A) 
and anchorage-independent growth in parental cells (Figure 2.16A and 2.17A). 
Even though agonist effects of S961 have been reported, we did not observe 
32 
 
S961-induced signaling or cell proliferation in these breast cancer cells (Figure 
2.21 and 2.22).  
In contrast, S961 blocked insulin-regulated signaling even at 
concentrations as low as 1 nM concentration in TamR cells (Figure 2.12B and 
2.13B). Similar sensitivity was reflected in anchorage-independent growth assay 
(Figure 2.16B and 2.17B) and cell cycle analysis (Figure 2.14B and 2.15B), 
where 1 nM concentration of S961 fully diminished insulin-stimulated colony 
formation growth and S-phase induction, respectively in MCF-7L TamR cells. A 
higher S961 concentration was needed to fully block insulin-stimulated growth in 
T47D TamR cells. Since TamR cells lack IGF1R, they do not respond to IGF-I 
stimulation.  
83-7 mAb down-regulates InsR, thus inhibiting insulin-stimulated signaling and 
growth in TamR cells.  
   Monoclonal antibody clone 83-7 (83-7 mAb) binds alpha-subunit of InsR 
allosterically without interfering insulin binding  [159] and is specific for InsR 
binding although its functional roles in cells are not well studied. The antibody 
has been reported to stimulate lipogenesis, inhibit lipolysis, and activate receptor 
kinase by cross-linking receptor molecules [160].  
To explore the effect of 83-7 mAb in cancer cells, we pre-treated 83-7 
mAb overnight before treating with IGF-I, IGF-II, or insulin in MCF-7L, T47D and 
TamR cells. As shown in Figure 2.18, 83-7 mAb did not induce receptor 
phosphorylation. In contrast, 83-7 mAb down-regulated InsR and effectively 
blocked IGF-II and insulin-stimulated IGF1R/InsR, IRS, AKT and MAPK 
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phosphorylation (Figure 2.18). To study the biological effects of InsR, anchorage 
independent growth assays showed that 83-7 mAb effectively inhibited insulin-
stimulated colony formation (Figure 2.19). Although 83-7mAb caused some InsR 
down-regulation in the parental cells, there was little to minimal inhibitory effect of 
83-7 mAb on MCF-7L and T47D parental cells in terms of IGF-I, IGF-II or even 
insulin-stimulated signaling and anchorage-independent growth (Figure 2.18 and 
2.19).  
Inhibition of InsR was not effective in parental breast cancer cells due to the 
presence of IGF1R/InsR hybrid receptors.   
To further explore why InsR inhibition was not effective in MCF-7L and 
T47D parental cells, we used immunoprecipitation and immunoblotting to 
examine the ability of these cells to express IGF1R/InsR hybrid receptors. Co-
immunoprecipitation studies showed that IGF1R/InsR hybrid receptors are 
present in MCF-7L and T47D parental cells but not in TamR cells because of 
their downregulation of IGF1R (Figure 2.20). As previously shown, S961 was not 
effective in parental cells. To inhibit IGF1R and hybrid receptors, we used 
HuEM164 (also known as AVE1642), an anti-IGF1R mAb shown to specifically 
bind IGF1R and result in its down-regulation [161]. In the parental cells, insulin 
signaling was more completely extinguished by the use of both IGF1R mAb and 
S961 (Figure 2.21 and 2.22).  
Similarly, when shIR transduced parental cells was treated with HuEM164, 
a synergistic inhibitory effect was achieved, as measured by IGF1R/InsR, IRS, 
AKT and MAPK phosphorylation. Unlike S961, down-regulation of InsR by 
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HuEM164 however was able to only partially block insulin-mediated signaling in 
parental cells (Figure 2.23 and 2.24). The most complete inhibition of ligand 
signaling was achieved by the combination of shIR#6 and HuEM164.    
83-7 and HuEM164 mAbs provided no synergistic benefits to ER+ breast cancer 
Since mAbs are commonly used to treat cancer in the clinic, we were 
curious if 83-7 would be a better choice for combination treatments. MCF-7L cells 
were treated with 83-7 and/or HuEM164 mAbs overnight prior to western blot 
analysis. Although the expression levels of IGF1R and InsR were significantly 
reduced in MCF-7L treated with HuEM164 and 83-7 mAbs, compared to 
individual treatment (Figure 2.25), IGF-II-mediated signaling was not fully 
suppressed., HuEM164 alone was sufficient to block IGF-I- and insulin-mediated 
signaling in MCF-7L, which is consistent to the previously shown results. To 
further evaluate the combinational benefits in a functional context, MTT 
monolayer proliferation assay and cell cycle analysis were performed. 
Interestingly, not only was 83-7 mAb not able to provide a combined inhibitory 
effect in conjunction with HuEM164, 83-7 mAb interfered with the function of 
HuEM164 in blocking IGF-I-driven monolayer proliferation (Figure 2.26) and cell 
cycle progression (Figure 2.27). 
Combination treatments of 83-7 and HuEM164 fully suppressed ligand-mediated 
signaling in triple negative breast cancer cells 
 MDA-MB-231 and MDA-MB-435 are triple-negative breast cancer (TNBC) 
cell lines. They both express moderate amounts of IGF1R and InsR and respond 
35 
 
to IGF-I, IGF-II and insulin stimulations. Unlike MCF-7L, 83-7 mAb alone inhibited 
insulin-mediated signaling in MDA-MB-231. The combination treatments of 83-7 
and HuEM164 mAbs synergistically blocked IGF-II-regulated signaling, which 
was not achieved with single agent inhibition (Figure 2.28). The western blot data 
of MDA-MB-435 was not clear because of the high basal level of p-AKT (Figure 
2.29). However, down-regulation of receptor levels by 83-7 and HuEM164 mAbs 
were additive. LCC6, which is a derivative of MDA-MB-435, can be an alternative 
TNBC model. Moreover, constitutively activation of MAPK was noticeable in 
these cell lines. 
Discussion 
While the insulin/InsR signaling system is responsible for glucose 
homeostasis; it is also a cellular growth factor. Metabolic syndrome associated 
with obesity and type II diabetes, both states of relative insulin resistance 
resulting in hyperinsulinemia are associated with cancer risk [162]. Breast cancer 
patients who have these conditions are more likely to suffer metastatic disease, 
disease recurrence, and mortality [163, 164]. When a number of anti-IGF1R 
mAbs trials failed to show benefits in cancer patients, one mechanistic 
explanation is the presence of InsR acting as a compensatory pathway to IGF1R 
inhibition and IGF1R loss [118]. Our endocrine resistant model showed greater 
sensitivity towards insulin when IGF1R expression level is lacking (Figure 2.1, 
2.2 and 2.3). Other studies have also shown similar pattern in prostate cancer 
and pancreatic neuroendocrine tumors in vivo, where InsR induces mitogenic 
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activities and compensates for IGF1R inhibition or resistance to anti-IGF1R [165, 
166].  
InsR exists in two isoforms: InsR-A and InsR-B due to alternative splicing 
of exon 11, differing by 12 amino acids. Previous studies have shown that InsR-B 
tends to be a metabolic receptor expressed in adult muscle, liver, and fat.  InsR-
B binds only insulin at physiological concentrations. In contrast, InsR-A, a 
predominant isoform during fetal development is commonly expressed in cancer 
and binds with high affinity to insulin and IGF-II [167, 168]. Up-regulation of InsR-
A has been reported in breast, ovarian, lung, colon cell lines and/or human 
tumors and is thought to mediate tumorigenesis and survivor in response to 
insulin and IGF-II [169-173]. However, our endocrine-resistant model did not 
show an increase in InsR-A/InsR-B ratio of mRNA level compared to parental 
cells (data not shown). To date, antibodies have not been developed that can 
distinguish between levels of InsR isoforms, thus the exact protein expression of 
isoforms is uncertain in cells. In tumors, the data regarding the role of InsR-A are 
derived from mRNA levels detected by PCR. Additional study is needed to 
determine if InsR-B has an important role in cancer biology.  
In this study, we blocked InsR function by three different techniques: 1.) 
genetic knockdown of InsR using lentiviral shRNA, 2.) competitively blocked of 
insulin binding to its receptor by S961 and 3.) down-regulation of InsR without 
affecting insulin binding by a mAb. These different techniques showed consistent 
results, where inhibiting InsR was effective in the inhibition of insulin-regulated 
signaling and growth in TamR breast cancer cells, but not in parental cells. 
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These data show that insulin signaling is important in endocrine resistant cells, 
but less relevant to parental MCF-7L and T47D cells. The presence of IGF1R or 
hybrid receptors and little of holo-InsR make insulin only a weak mitogen in 
parental cells (Figure 2.20). However, in TamR cells, where there is little IGF1R, 
InsR becomes the predominant receptor driving insulin- (and IGF-II) stimulated 
growth. Thus, InsR is an important target in TamR cells. Moreover, IGF1R/InsR 
hybrid receptors allows cancer cells to expand their ligand binding capacity. 
Insulin can still signal through the other available IGF1R heterodimer upon InsR 
inhibition; likewise, IGF-I may signal through InsR in a hybrid confirmation 
suggesting single target inhibition of IGF1R or InsR is not sufficient to suppress 
hybrid receptor signaling.  
Unfortunately, there is no reliable method to quantify the level of hybrid 
receptors in cells or patient tumors making it difficult to predict response to 
antibody-based therapy on only examining levels of receptor expression. 
However, the use of broader range of receptor biochemical inhibition such a TKI 
may provide a better therapeutic advantage.    
TNBCs are the most aggressive form of breast cancer. They remain non-
targetable due to their vast heterogeneity and lack of the three markers (ER-, 
PR- and HER2-). There is no targeted therapy approved for TNBC. This type of 
tumors is usually treated with conventional chemotherapy and radiation therapy.  
In our study, the signaling result of IGF1R/InsR blocking antibodies did seem 
promising in MDA-MB-231 (Figure 2.28), even though we have yet to show 
functional data to prove their efficacy. Our lab has shown that down-regulation of 
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InsR using shRNA reduced tumor growth and metastasis of LCC6 in mice [130], 
suggesting that TNBC may benefit from InsR/IGF1R inhibition. Similar functions 
of insulin receptor have been described in an ER-negative model of mouse 
breast cancer [174]. In this system, InsR suppression was necessary to inhibit 
murine breast cancers in both normal and hyper-insulinemic hosts. 
The major concern about targeting InsR is the resulting disruption of 
glucose homeostasis in normal tissues. Hyperglycemia can be managed by 
metformin, a commonly used drug for type 2 diabetes  that reduces hepatic 
gluconeogenesis, circulating insulin level, and stimulates glucose uptake in 
muscle independent of insulin [175, 176]. However, the ability of metformin to 
directly affect cancer cell biology outside of modulating serum insulin levels is not 
understood. While there are preclinical data suggesting that metformin has little 
effect in models of non-diabetic rodent models [177], the clinical benefits of 
metformin in non-diabetic women with breast cancer awaits reporting of an 
adjuvant clinical trial where women were assigned to receive metformin or 
placebo for five years after surgical therapy for breast cancer (NCT01101438).  
In summary, direct targeting of InsR would be a preferable strategy. Here, 
we show that monoclonal antibodies and a competitive peptide inhibitor have 
active against InsR, but there could have significant metabolic effects in vivo. As 
noted the two isoforms of InsR provide a theoretical strategy to only inhibit the 
cancer associated function of InsR signaling. If InsR-A specific agents could be 
developed, then this would not perturb the metabolic functions of InsR-B in 
normal tissues.   
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Figure 2.1. Insulin-mediated PI3K and MAPK activation was stronger in 
TamR cells compared to their parental counterparts.  
(A) MCF-7Ls and (B) T47Ds were plated, serum starved for 24 hours and treated 
with increasing concentrations of insulin for 15 minutes. Whole cell lysates were 
collected, separated by SDS-PAGE and subjected to the indicated 
immunoblotting analyses. 
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Figure 2.2. Insulin treatment stimulated greater monolayer proliferation in 
TamR cells compared to their parental counterparts.  
Cell monolayer growth of (A) MCF-7Ls and (B) T47Ds were measured using 
MTT proliferation assay. Cells were serum starved for 24 hours and then treated 
with increasing concentrations of insulin. Readings were taken 5 days later. The 
results were normalized to untreated group. Values were normalized to untreated 
group and were presented as fold change (mean ± standard deviation, n=3). 
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Figure 2.3. Insulin stimulated more colony formation in TamR cells 
compared to their parental counterparts 
Anchorage-independent growth assay was carried out on (A) MCF-7Ls and (B) 
T47Ds. Colonies formed were counted 14 days and 20 days later, respectively.  
Values were normalized to untreated group and were presented as fold change 
(mean ± standard deviation, n=3). 
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Figure 2.4. Knockdown of InsR using short hairpin RNA reduced insulin-
regulated signaling in TamR cells, but not in their parental cells. 
(A) MCF-7Ls and (B) T47Ds were InsR knock-downed with lentiviral shRNA 
(shIR#2, shIR#6) or plasmid control (shSrcb or pLKO.1). InsR protein levels were 
determined using Western blot analyses. Cells were plated, serum started for 24 
hours and treated with or without 10nM insulin for 15 minutes. Whole cell lysates 
were collected, separated by SDS-PAGE and subjected for indicated 
immunoblotting analyses.  
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Figure 2.5. Measurement of mRNA level of InsR after knockdown using 
short hairpin RNA.  
InsR mRNA expression levels of (A) MCF-7Ls and (B) T47Ds were determined 
using qRT-PCR analysis, total RNA was collected from cells in full media. Data 
was normalized to housekeeping gene, glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH). Results represent mean ± standard deviation of 
triplicates from three independent experiments. 
A 
B 
45 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6. Knockdown of InsR using short hairpin RNA abolished insulin-
driven monolayer proliferation in TamR cells.  
Cell monolayer growth was measured using MTT assay. Transduced MCF-7L 
cells were serum starved for 24 hours and treated with or without insulin for 5 
days. Values were normalized to untreated group and were represented in fold 
change (mean ± standard deviation, n=3). Two-way ANOVA with Bonferroni 
comparison was performed to identify significance among untreated versus 
treated groups and shIR versus control groups. **, p<0.01.  
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Figure 2.7 knockdown of InsR affected the distribution of cell cycle phases 
in TamR cells, but not in the parental cells.  
Cells were plated, serum starved for 24 hours and treated with indicated insulin 
concentrations overnight. Cell cycle analysis was performed using flow 
cytometry. 
 
Cell lines Insulin (nM) 
 Phases (%)  
G0/G1 S G2/M 
T47D 
pLKO.1 
0 53.0 ± 5.0 24.8 ± 2.5 11.3 ± 5.4 
1 53.8 ± 6.8 25.6 ± 1.4 10.7 ± 6.1 
10 41.9 ± 8.2 33.3 ± 2.2 13.1 ± 0.8 
T47D 
shIR#2 
0 50.5 ± 2.4 26.9 ± 0.7 11.0 ± 1.4 
1 52.4 ± 8.6 25.0 ± 3.7 12.1 ± 0.8 
10 40.4 ± 8.7 33.8 ± 5.5 13.4 ± 1.2 
T47D 
shIR#6 
0 52.2 ± 8.1 27.1 ± 6.2 7.5 ± 1.3 
1 49.2 ± 5.9 28.1 ± 6.0 10.9 ± 0.5 
10 35.9 ± 8.1 33.6 ± 1.3 10.8 ± 7.0 
T47D TamR 
pLKO.1 
0 60.3 ± 6.5 21.0 ± 5.1 13.0 ± 1.3 
1 55.2 ± 4.2 27.9 ± 6.4 10.7 ± 3.9 
10 42.0 ± 2.8 36.8 ± 1.6 10.7 ± 2.6 
T47D TamR 
shIR#2 
0 63.9 ± 3.6 20.3 ± 1.7 8.9 ± 0.2 
1 52.5 ± 8.6 19.8 ± 2.0ns 17.7 ± 5.8 
10 49.0 ± 7.1 25.8 ± 1.0* 14.1 ± 3.4 
T47D TamR 
shIR#6 
0 54.8 ± 9.9 19.5 ± 0.7 12.8 ± 2.6 
1 54.7 ± 8.5 18.6 ± 1.4* 15.3 ± 4.9 
10 48.6 ± 5.0 22.8 ± 1.9*** 14.8 ± 1.5 
Mean ± SD (n = 3) ns, not significant; *, p<0.05; ***, p<0.001  
shIRs versus control of relative treatment groups 
 
Cell lines Insulin (nM) 
Phases (%) 
G0/G1 S G2/M 
MCF-7L  
shScrb 
0 47.8 ± 7.8 27.4 ± 1.2 9.28 ± 3.8 
1 49.4 ± 4.1 29.0 ± 1.9 14.6 ± 2.9 
10 45.5 ± 3.0 35.1 ± 1.5 11.9 ± 5.1 
MCF-7L  
shIR#2 
0 51.2 ± 6.6 27.8 ± 2.8 9.9 ± 5.7 
1 53.9 ± 3.7 27.2 ± 2.6 12.4 ± 1.6 
10 49.4 ± 7.3 35.7 ± 5.1 6.71 ± 4.0 
MCF-7L  
shIR#6 
0 49.6 ± 8.2 30.9 ± 9.7 11.6 ± 3.8 
1 52.1 ± 7.3 28.2 ± 2.0 11.7 ± 3.2 
10 44.4 ± 5.5 38.1 ± 4.1 7.7 ± 7.0 
MCF-7L TamR  
shScrb 
0 55.3 ± 1.9 24.5 ± 2.4 14.4 ± 1.1 
1 39.0 ± 15.3 34.2 ± 1.4 11.9 ± 4.6 
10 41.4 ± 1.7 35.6 ± 2.7 13.8 ± 4.6 
MCF-7L TamR  
shIR#2 
0 39.8 ± 1.6 17.8 ± 1.4 26.2 ± 3.8 
1 39.8 ± 3.5 16.3 ± 1.6*** 28.5 ± 6.6 
10 38.0 ± 3.5 22.1 ± 3.1*** 22.0 ± 5.3 
MCF-7L TamR  
shIR#6 
0 45.7 ± 3.0 20.3 ± 4.3 19.2 ± 3.8 
1 43.7 ± 5.9 19.7 ± 2.7*** 21.2 ± 2.2 
10 44.6 ± 5.6 20.7 ± 0.1*** 19.7 ± 5.8 
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Figure 2.8. Knockdown of InsR using short hairpin RNA abolished 
anchorage-independent growth in TamR cells.  
Anchorage-independent growth of lentiviral transduced (A) MCF-7Ls and (B) 
T47Ds was measured after 19 days and 25 days, respectively using soft agar 
assay. Values were normalized to untreated group and were represented in fold 
change (mean ± standard deviation, n=3). Two-way ANOVA with Bonferroni 
comparison was performed to identify significance among untreated versus 
treated groups and shIR versus control groups. **, p<0.01. 
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Figure 2.9. Expression of hIR-GFP cDNA mildly restored InsR expression 
and signaling.  
Lentiviral transduced MCF-7L TamR cells were transiently transfected with hIR-
GFP cDNA and selected under 500 µg/mL G418 for at least a week. Cells were 
serum starved for 24 hours and treated with 10nM insulin for 15 minutes before 
collecting for SDS-PAGE and immunoblotting analyses.  
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Figure 2.10, Expression of hIR-GFP cDNA reversed the knockdown effect of 
shIR in MCF-7L TamR cells.   
Cell monolayer growth was carried out using MTT assay, where the cells were 
serum starved for 24 hours and treated without and with insulin for 5 days before 
the reading was taken. Graphs represent mean ± standard deviation of 
triplicates. Two-way ANOVA with Bonferroni comparison was performed. **, 
p<0.01; ***, p<0.001. 
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Figure 2.11. Exogenous expression of human InsR gene facilitated insulin-
regulated signaling and cell growth in TamR but not in the parental cells. 
MCF-7L and TamR were transiently transfected with hIR-GFP under 500 µg/mL 
G418 for at least a week. (A) Cells were serum starved for 24 hours and treated 
with or without 10nM insulin for 15 minutes. Whole cell lysates were collected, 
separated by SDS-PAGE and subjected for indicated immunoblotting analyses. 
(B) Cell monolayer growth was measured using MTT assay. Cells were serum 
starved for 24 hours and treated with indicated insulin concentrations for 6 days 
before the reading was taken. Graphs represent mean ± standard deviation of 
triplicates. Two-way ANOVA with Bonferroni comparison was performed. ns = not 
significant; **, p<0.01. 
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Figure 2.12. S961 inhibited insulin-mediated PI3K/MAPK signaling in MCF-
7L TamR, but not in the parental MCF-7L cells.  
(A) MCF-7L and (B) MCF-7L TamR cells were serum starved overnight and pre-
treated with varying concentrations of S961 for 30 minutes before treating the 
cells with either 10nM insulin or 5nM IGF-I for 10 minutes. Whole cell lysates 
were separated by SDS-PAGE and immunoblotted for indicated antibodies. 
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Figure 2.13. S961 inhibited insulin-mediated PI3K/MAPK signaling in T47D 
TamR, but not in the parental T47D cells.  
(A) T47D and (B) T47D cells were serum starved and pre-treated with increasing 
concentrations of S961 for 30 minutes before treating the cells with either 10nM 
insulin or 5nM IGF-I for 10 minutes. Whole cell lysates were separated by SDS-
PAGE and immunoblotted for indicated antibodies.  
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Figure 2.14. S961 inhibited S phase induction stimulated by insulin in MCF-
7L TamR, but not in the parental MCF-7L cells.  
(A) MCF-7L and (B) MCF-7LTamR cells were plated, serum starved for 8 hours 
before treating with varying concentrations of S961 and either 10nM insulin or 
5nM IGF-I overnight. Cell cycle analysis was performed using flow cytometry and 
analyzed using FlowJo.  
 
MCF-7L 
treatment 
S961 
(nM) 
Phases (%) 
G0/G1 S G2/M 
SFM 0 64.9 20.4 14.7 
Insulin 
0 32.7 45.0 22.3 
1 34.9 44.4 20.7 
10 39.5 43.0 17.5 
100 38.4 41.8 19.8 
IGF-I 
0 34.7 48.2 17.1 
1 34.2 40.1 25.7 
10 33.8 47.2 19.1 
100 34.7 46.2 19.2 
 
MCF-7L TamR 
treatment 
S961 
(nM) 
Phases (%) 
G0/G1 S G2/M 
SFM 0 66.0 19.1 15.0 
Insulin 
0 30.9 32.7 36.4 
1 60.1 24.3 15.6 
10 64.6 19.7 15.7 
100 64.3 17.1 19.4 
IGF-I 
0 59.9 26.0 14.1 
1 59.2 20.1 20.7 
10 66.9 20.2 12.9 
100 63.0 20.4 16.7 
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Figure 2.15. S961 inhibited S phase induction stimulated by insulin in T47D 
TamR, but not in the parental T47D cells.  
(A) T47D and (B) T47D TamR cells were plated, serum starved for 24 hours 
before treating with increasing concentrations of S961 in conjunction with either 
10nM insulin or 5nM IGF-I overnight. Cell cycle analysis was performed using 
flow cytometry. 
 
T47D 
treatment 
S961 
(nM) 
Phases (%) 
G0/G1 S G2/M 
SFM 0 50.5 28.4 11.5 
IGF-I 
0 23.3 50.9 10.6 
1 34.4 42.6 8.3 
10 30.5 45.6 5.2 
100 42.8 34.8 9.9 
Insulin 
0 30.5 43.5 14.7 
1 34.2 45.1 9.2 
10 34.4 44.2 13.5 
100 31.7 42.2 12.9 
 
T47D TamR 
treatment 
S961 
(nM) 
Phases (%) 
G0/G1 S G2/M 
SFM 0 61.9 17.4 11.9 
IGF-I 
0 50.8 22 17.9 
1 53.7 20.4 17.5 
10 52.2 23.9 10.9 
100 54.0 22.5 13.4 
Insulin 
0 40.1 37.3 10.3 
1 46.9 30.5 16.9 
10 54.7 22.1 15.0 
100 55.4 19.8 16.2 
A 
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Figure 2.16. S961 inhibited insulin-driven colony formation in MCF-7L 
TamR, but not in the parental MCF-7L cells.  
Anchorage-independent growth assay was carried out on (A) MCF-7L and (B) 
MCF-7L TamR cells treated with varying concentrations of S961 and either 10nM 
insulin or 5nM IGF-I. Treatments were spiked in after 7 days.  Colonies formed 
were counted 14 days later. Two-way ANOVA with Bonferroni comparison was 
performed to compare between treated and untreated group. *, p<0.05; **, 
p<0.01.   
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Figure 2.17. S961 inhibited anchorage-independent growth in T47D TamR, 
but not in the parental T47D cells.  
Soft agar assay was carried out on (A) T47D and (B) T47D TamR cells treated 
with increasing concentrations of S961 and either 10nM insulin or 5nM IGF-I. 
Treatments were spiked in after 7 days. Colonies formed were counted 15 days 
after plated. Two-way ANOVA with Bonferroni comparison was performed to 
compared between treated and untreated group. ***, p<0.001.   
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Figure 2.18 Down-regulation of InsR by anti-InsR monoclonal antibody 
clone 83-7 inhibited insulin-stimulated signaling in TamR cells.  
MCF-7L and T47D cells were serum starved and pre-treated with 2 µg/mL of 83-
7 overnight before treating with either 5nM IGF-I, 10nM IGF-II or 10nM insulin for 
15 minutes. Whole cell lysates were collected, separated by SDS-PAGE and 
subjected for indicated immunoblotting analyses. 
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Figure 2.19. Monoclonal antibody clone 83-7 against InsR inhibited 
anchorage-independent growth in TamR cells. 
Anchorage-independent growth assay was carried out on MCF-7Ls and T47Ds 
treated with 2 µg/mL of 83-7 without or with either 10nM IGF-I or 10nM insulin. 
Colonies formed were counted 14 days for MCF-7Ls and 21 days for T47D cells 
after first plated. Two-way ANOVA with Bonferroni comparison was performed to 
identify significance among untreated vs. treated groups. *, p<0.05; ***, p<0.001.  
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Figure 2.20. IGF1R/InsR hybrid receptors were present in MCF-7L and T47D 
parental cells. 
The presence of IGF1R/InsR hybrid receptors was identified via 
immunoprecipitation (IP). Whole cell lysates were collected in full media and 
immunoprecipitated with either anti-InsR antibody or mouse IgG overnight. IP 
was then resolved with SDS-PAGE and subjected for IGF1R immunoblotting. 
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Figure 2.21. HuEM164 was required to fully suppress IGF-I- and insulin-
stimulated signaling in MCF-7L parental cells, which was not achieved with 
S961 alone.  
MCF-7L parental cells were serum starved overnight, pre-treated with 20 µg/mL 
HuEM164 for 3 hours and varying concentrations of S961 for 30 minutes before 
exposing to either 10nM insulin or 5nM IGF-I for 10 minutes. Whole cell lysates 
were collected, separated by SDS-PAGE and subjected for immunoblotting 
analyses. 
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Figure 2.22. Combination treatment of S961 and HuEM164 effectively 
blocked insulin-mediated signaling in T47D parental cells.  
T47D parental cells were serum starved overnight, pre-treated with 20 µg/mL 
HuEM164 for 3 hours and varying concentration of S961 for 30 minutes before 
treating with either 10nM insulin or 5nM IGF-I for 10 minutes. Whole cell lysates 
were collected and separated by SDS-PAGE and subjected for immunoblotting 
analyses.   
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Figure 2.23. HuEM164 partially down-regulated InsR and blocked insulin-
stimulated signaling in MCF-7L parental cells.  
Lentiviral transduced MCF-7L cells were serum starved overnight and pre-treated 
with 20 µg/mL HuEM164 overnight before exposing to either 10nM insulin or 5nM 
IGF-I for 15 minutes. Whole cell lysates were collected, separated by SDS-PAGE 
and subjected for indicated immunoblotting analyses. 
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Figure 2.24. IGF1R down-regulation is necessary to effectively block 
insulin-regulated signaling in T47D parental cells.  
Lentiviral transduced T47D parental cells were serum starved for 24 hours and 
pre-treated with 20 µg/mL HuEM164 for 1 hour before treating with 5nM IGF-I or 
10nM insulin for 15 minutes. Whole cell lysates were collected, separated by 
SDS-PAGE and subjected for indicated immunoblotting analyses.   
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Figure 2.25. HuEM164 and 83-7 mAbs did not synergistically block ligand-
mediated signaling in MCF-7L, compared to single targeting agent.  
MCF-7L cells were plated, serum-starved overnight and pre-treated with 20 
µg/mL of HuEM164 and 10 µg/mL of 83-7 antibodies overnight before exposing 
to either 20nM insulin, 10nM IGF-I and 20nM IGF-II for 15 minutes. Whole cell 
lysates were collected, separated by SDS-PAGE and subjected for indicated 
immunoblotting analyses.  
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Figure 2.26. Co-treatments of 83-7 and HuEM164 mAbs provided no 
combined inhibition of ligand-driven monolayer proliferation in MCF-7L 
compared to HuEM164 alone.   
MCF-7L cells were plated, serum-starved for 24 hours and treated with 20 µg/mL 
of HuEM164 or/and 10 µg/mL 83-7 antibodies in combination with either 10 nM 
insulin, 5 nM IGF-I or 10 nM IGF-II. Readings were taken 5 days later and the 
values were represented as mean ± standard deviation in triplicates. T-test 
analysis was performed to identify significance between HuEM164 treated vs. 
untreated group. *, p,0.05.  
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Figure 2.27. Co-treatments of 83-7 and HuEM164 mAbs provided no 
combined inhibition of cell cycle progression in MCF-7L, compared to 
HuEM164 alone.    
Cells were plated, serum-starved for 24 hours and treated with 20 µg/mL of 
HuEM164 or/and 10 µg/mL 83-7 antibodies in combination with either 10 nM 
insulin, 5 nM IGF-I or 10 nM IGF-II overnight. Cell cycle analysis was performed 
using flow cytometry.  
 
 
67 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.28. Co-treatments of 83-7 and HuEM164 mAbs synergistically 
blocked IGF-II-regulated signaling in MDA-MB-231.  
Cells were plated, serum-starved overnight and pre-treated with with 20 µg/mL of 
HuEM164 and 10 µg/mL of 83-7 antibodies overnight before exposing to either 
20nM insulin, 10nM IGF-I and 20nM IGF-II for 15 minutes. Whole cell lysates 
were collected, separated by SDS-PAGE and subjected for indicated 
immunoblotting analyses.  
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Figure 2.29. Co-treatments of 83-7 and HuEM164 mAbs synergistically 
down-regulated IGF1R and InsR expression levels in MDA-MB-435. 
Cells were plated, serum-starved overnight and pre-treated with with 20 µg/mL of 
HuEM164 and 10 µg/mL of 83-7 antibodies overnight before exposing to either 
20nM insulin, 10nM IGF-I and 20nM IGF-II for 15 minutes. Whole cell lysates 
were collected, separated by SDS-PAGE and subjected for indicated 
immunoblotting analyses 
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Introduction 
Personalized medicine has become the next focus in cancer therapy. A 
one-treatment-fits-all approach is no longer appropriate in treating complex 
heterogenous disease such as breast cancer. Many of the distress from 
unrewarding clinical evaluations and the hinder in pharmaceutical industry could 
directly attributed to a lack of understanding and appreciation of human disease 
complexity and variability. It was only recently that the industry started to realize 
the need for tailoring drug to certain groups of populations and the importance of 
phenotyping efforts. This has stimulated the demand for protein engineering to 
develop effective protein drugs. Molecular profiles of tumors may provide insights 
and opportunities for the development of therapies to improve clinical outcomes 
for breast cancer.  
While systemic inhibition of InsR may disrupt metabolism in an unselected 
patient group, certain subpopulations of cancer patients including non-diabetic 
endocrine-resistant breast cancer patients with increased InsR expression or 
insulin sensitivity may benefit from InsR inhibition. Yet, there are no reliable tools 
available for InsR quantification or specific InsR inhibition. The only drugs that 
inhibit InsR – linsitinib (OSI-906) and BMS-754807 – exist as dual IGF1R/InsR 
tyrosine kinase inhibitors. Evidence suggested OSI-906 was well tolerated and 
antitumor activity was observed in phase I clinical trial [178]. A phase II trial 
testing BMS-754807 in ER+ breast cancer patients resistant to aromatase 
inhibitors has completed (NCT01225172) but the results have not been 
disclosed.   
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Antibodies, the most commonly studied target specific binding molecules 
have long been used as therapeutic and diagnostic tools in medicine as well as 
in basic and applied research. Numerous antibodies have been approved against 
many diseases from cancer to viral and immunologic diseases [179-181]. Despite 
their valuable and widespread applicability, antibodies suffer from several 
limitations including limited tissue penetration [182-184], complex bispecific 
generation, suboptimal pharmacokinetic clearance for diagnostic imaging [183, 
185], reduced ease to target select epitopes [186], modest instability and high 
production cost [187]. Non-immunoglobulin protein scaffolds have arisen as an 
alternative strategy including single domains that are relatively small (<15 kDa), 
structurally stable, tolerable to mutation, and do not require disulfide bonds and 
post-translational modification for activity [188]. A number of non-immunoglobulin 
scaffolds have been developed and tested in clinical trials [188]. Adnectin CT-
322, an engineered 10th type III domain of human fibronectin targeted against 
VEGFR-2, showed tolerable side effects and promising antitumor activity in 
patients with variety of solid tumors in phase I [189] although phase II trial of CT-
322 did not show efficacy in recurrent glioblastoma [190]. More studies are 
underway with other adnectins (NCT02515669). ABY-025, an engineered 
affibody targeting HER2 receptor was able to discriminate HER2 status in 
metastatic breast cancer in patients under positron emission tomography (PET) 
imaging [191]. These and other examples have shown that small protein 
scaffolds can be engineered and selected against a wide array of targets and 
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their applications can range from basic science to diagnostic and therapeutic 
functions.  
In this study, we used yeast surface display [192, 193], a platform for 
library screening and binder isolation to develop binders to InsR based on the T7 
gene 2 protein (Gp2) scaffold [194]. Gp2 is a 45-amino-acid domain with two 
solvent-exposed loops (Figure 3.1A) capable of mutation to generate new 
binding function while retaining structural and thermal stability with midpoints of 
thermal denaturation of 65-80°C [194]. A Gp2 domain engineered to bind 
epidermal growth factor receptor was effectively used as a PET probe for in vivo 
imaging in murine xenograft tumor models [195]. Although Gp2 domain has been 
engineered against various targets, no Gp2 binder has so far been shown to 
exhibit biological activity on cancer cells. Here, we evolved three Gp2 variants 
exhibiting strong binding affinity against cell-surface InsR. The domains inhibit 
insulin-regulated growth in endocrine-resistant and –sensitive breast cancer 
models and exhibit differential inhibition of receptor and downstream signaling. 
Notably this inhibition is observed even though one of the variants exhibits 
enhanced binding upon insulin co-treatment. These agents are the first non-
immunoglobulin proteins that inhibit InsR function in breast cancer.  
Results 
Discovery and evolution of InsR-specific Gp2 binders through yeast surface 
display 
InsR-specific Gp2 domains were discovered and evolved through yeast 
surface display and various enrichment and depletion technologies including 
73 
 
magnetic bead selection and fluorescence activated cell sorting (FACS) with 
recombinant InsR ectodomain (rInsR) and detergent solubilized lysate of cells 
expressing InsR-GFP fusion (Figure 3.2A). Yeast displaying the naïve Gp2 
library underwent two sorts of rInsR binding enrichment via magnetic beads and 
one FACS for full-length Gp2 before parallel error-prone PCR targeting the loops 
and the genes of enriched Gp2 variants. The resultant Gp2 population was 
further enriched with two sorts on rInsR-coated magnetic beads, one FACS with 
rInsR and one FACS with InsR-expressing cell lysate before undergoing a 
second round of mutations. During the final evolutionary round, the mutagenized 
InsR-enriched Gp2 population was sorted against cell lysate containing InsR-
GFP and the top 2% of InsR binders were isolated via FACS (Figure 3.2B, 
middle). Appreciable binding was not observed for the enriched Gp2 population 
to GFP-only cell lysates or yeast displaying non-enriched Gp2 control incubated 
with InsR-GFP lysates, indicating that the population evolved a Gp2—InsR 
interaction rather than binding between other elements of the selection process 
(Figure 3.2B, left and right). 
Among twenty selected top InsR binders from FACS, eight clones had 
unique protein sequences and proceeded for protein production in E. coli. Six 
variants had suitable protein yield in the soluble fraction of E. coli and were 
evaluated for binding to InsR overexpressing HEK293T cells. Two variants 
showed weak binding against cell-surface InsR; while a third variant showed no 
InsR specificity as it was not able to differentiate binding between InsRhigh and 
InsRlow cell lines. Three variants, name Gp2 #1, #5 and #10 exhibited strong 
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binding to cell-surface InsR (Figure 3.3). Gp2 #1 has unique loop sequences 
whereas Gp2s #5 and #10 have equivalent loops but a single amino acid 
difference at framework position 24 (Figure 3.4B). The purity and molecular 
weights (7 kDa with C-terminal His6 tag) of purified proteins were verified using 
SDS-PAGE (Figure 3.4A).  
Affinity titration of Gp2 variants  
To measure the affinity of soluble Gp2 variants against cell-surface InsR 
and further evaluate specificity, two cell types (Figure 3.5A) — InsR-GFP 
overexpression of HEK293T (InsRhigh) and GFP-control transduced HEK293T 
(InsRlow) – were labeled with ranging concentrations of soluble Gp2 proteins. 
Titration curves indicate strong binding of soluble Gp2 variants against cell-
surface InsR with low nanomolar affinity. The KD values for Gp2 variants #1, #5 
and #10 are 13 ± 14 nM, 2.4 ± 0.4 nM and 12 ± 9.0 nM, respectively (Figure 3.3). 
Unevolved Gp2 control does not bind InsR overexpressing cells (Figure 3.5B). 
Interestingly, Gp2 #1 reduced binding capacity after reaching a saturating point 
at very high concentration (1 µM), perhaps due to a high-dose “hook-effect” 
limiting antibody-based detection [196, 197] or a reversible conformational 
change at high concentration. Notably, other functional assays in the study were 
performed at nanomolar concentrations where this phenomenon is not observed. 
Moreover, this scenario was not observed with Gp2 #5 and #10.  
Minimal binding of Gp2 variants to IGF1R 
 Since InsR is closely related to IGF1R, sharing 45-65% domain dependent 
sequence and activating almost identical downstream signaling pathways [4, 5, 
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17], it is important to examine whether the Gp2 variants are able to distinguish 
IGF1R from InsR. The tamoxifen resistant MCF-7L TamR and T47D TamR cell 
lines were shown to have mild to moderate increased levels of InsR expression 
compared to their parental cell lines, but lack IGF1R expression [148], making 
them a good model for this study. Cells were labeled with either anti-InsR 
antibody, anti-IGF1R antibody or 100 nM soluble Gp2, followed by AF647-
conjugated anti-His antibody to better understand the binding capacity of these 
Gp2 relative to the commercially available antibodies. Gp2#5 and Gp2#10 bound 
greater to the TamR cells compared to their parental cells (Figure 3.6B and 
3.7B), which is consistent to that of anti-InsR antibody (Figure 3.6A and 3.7A).  
While antibody labelling demonstrated relatively similar IGF1R and InsR 
expressions in both MCF-7Ls and T47Ds, Gp2#1 also showed comparable 
binding to the parental and TamR in both cell lines, suggesting that Gp2#1 may 
have some weak cross-reaction with IGF1R. 
Inhibition of IGF-II/insulin-stimulated cell proliferation in breast cancer cells 
 TamR cells derived from estrogen receptor positive cell lines not only lack 
IGF1R expression but also depend on InsR signaling for cell growth compared to 
their parental cells [198]. To elucidate how these Gp2 variants affect biological 
function in these breast cancer cells, an MTT assay was used to access cell 
monolayer growth in MCF-7L (Figure 3.8A) and MCF-7L TamR cells (Figure 
3.8B). All three Gp2 variants inhibited insulin-stimulated growth in both MCF-7L 
and MCF-7L TamR cells in a dose-dependent manner, whereas non-binding Gp2 
control elicited no effect (Figure 3.10). All three Gp2 variants inhibited IGF-II-
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stimulated monolayer growth in MCF-7L TamR cells but insignificant inhibition – 
even at 200 nM – was observed on IGF-I regulated growth in MCF-7L cells. In 
the absence of IGF1R in MCF-7L TamR cells, IGF-II signals through InsR, 
whereas IGF-I signals via IGF1R in MCF-7L [199]. These results suggest that the 
inhibitory effects of Gp2 variants are specific to InsR-regulated growth. Gp2 
variants yield insignificant reduction on the basal growth in MCF-7L and MCF-7L 
TamR cells. 
 The analogous experiment was repeated with T47D (Figure 3.9A) and 
T47D TamR cells (Figure 3.9B). Overall, T47D TamR cells have a higher basal 
growth compared to T47D parental cells and yield results consistent to those of 
MCF-7L TamR, where the Gp2 variants completely blocked insulin-regulated cell 
growth. Since IGF-II-stimulated growth was not strong in these cells, the 
inhibitory effects of Gp2 #5 and #10 were not significant compared to the Gp2 
untreated groups. In contrast, toxicity was observed in T47D TamR cells treated 
with 200 nM of Gp2 #1 as the growth dropped below the basal level of the 
comparable untreated group. The T47D parental cell line exhibited some 
analogous behavior to MCF-7L in that Gp2 #1 inhibited insulin-driven growth and 
Gp2 #5 and #10 did not significant inhibit IGF-I-driven growth. However, T47D 
also showed several divergent outcomes relative to MCF-7L. Gp2 #1 had a 
strong inhibitory effect on IGF-I-regulated growth and Gp2 # 5 and #10 were not 
appreciable inhibitors of insulin-driven growth. Consistent to MCF-7L’s growth 
result, Gp2 variants blocked insulin-driven, but not IGF-I-driven, cell cycle 
progression in MDA-MB-231 cells and kept the cells arrested at G0/G1 phases 
77 
 
(Figure 3.11). To further examine if these variants inhibited growth by inducing 
cell death, cleaved PARP was measured by flow cytometry. Results showed that 
Gp2 variants did not significantly induce apoptosis in MCF-7L nor MDA-MB-231, 
suggesting that Gp2 itself is not cytotoxic (Figure 3.12). 
Differential effects of Gp2 variants on insulin/IGF signaling in breast cancer cells 
 To better understand the underlying mechanism of Gp2-mediated growth 
inhibition on breast cancer cells, receptor and effector phosphorylation analysis 
was carried out after various treatments with growth factors and Gp2 variants in 
MCF-7Ls (Figure 3.13), T47Ds (Figure 3.14) and their TamR derivatives. None of 
the Gp2 variants exhibited receptor activation in any of the cell lines. Overall, 
despite inhibiting growth, Gp2 #1 did not block insulin-mediated signaling in 
MCF-7L and T47D parental cells, as measured by phosphorylation of 
InsR/IGF1R, IRS (pY-20), AKT, p70S6K and MAPK. Similarly, in TamR cells, 
Gp2 #1 inhibits insulin-driven growth but is predominantly passive towards the 
tested signaling pathways with the exception of p70S6K inhibition in T47D TamR. 
Conversely, inhibition of InsR/IGF1R and MAPK phosphorylation are in accord 
with growth inhibition in MCF-7L TamR with IGF-II treatment. IGF-II driven 
signaling in T47D TamR was below the detection limit.  
 In T47D expressing IGF1R, Gp2 #1’s inhibition of IGF-I-driven growth is in 
accord with AKT and p70S6K inhibition. Despite not impacting growth, Gp2 #1 
strongly blocked IGF-I-mediated InsR/IGF1R and MAPK activation, and weakly 
inhibited AKT activation in MCF-7L parental cells. Gp2 #5 and #10 inhibited 
insulin- and IGF-II-driven growth in both TamR cell types in accord with blocking 
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phosphorylation of most tested molecules and exhibited minimal inhibition of 
insulin-mediated MAPK activation in MCF-7L TamR. IGF-II-driven 
phosphorylation in T47D TamR cells was below the detection limit. In parental 
cells, Gp2 #5 and #10 did not impact insulin-driven signaling, which coordinated 
with sustained growth in T47D but countered the observed growth inhibition in 
MCF-7L. Consistent with growth experiments, both Gp2 #5 and #10 had little 
effect on IGF-I signaling in MCF-7L parental cells except that Gp2 #10 blocked 
receptor phosphorylation at higher concentration and both Gp2s modestly 
inhibited AKT. Both variants inhibited IGF-I-mediated signaling to MAPK, AKT 
and p70S6K activation in T47D parental cells.  
 As the signaling results of MCF-7L and T47D were varying, two other 
triple negative cell lines, MDA-MB-231 and MDA-MB-435 were tested. The Gp2 
variants blocked insulin-, but not IGF-I-stimulated AKT activation in MDA-MB-435 
cells. Surprisingly, an opposite result was observed in MDA-MB-231. The Gp2 
variants strongly blocked IGF-I-mediated signaling, but exhibited little to no 
inhibition on insulin-mediated signaling (Figure 3.15). These diverse signaling 
outcomes in different cell lines are consistent with different abundance of 
IGF1R/InsR hybrid receptors measured by immunoprecipitation (Figure 3.16). 
When the cells express predominantly holo-InsR and minimal hybrid receptors – 
as in MDA-MB-435 – the inhibition of InsR signaling is straightforward. In 
contrast, in MCF-7L and MDA-MB-231 cells that express an abundance of hybrid 
receptors, Gp2 may have minimal inhibitory effects on insulin but overlapping 
impacts on IGF-I signaling, as IGF-I is the preferred ligand for hybrid receptors. 
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Therefore, in term of signal transduction, it is not surprise that InsR-evolved Gp2 
variants failed to block InsR existed in a hybrid context. 
Positive cooperativity of insulin on binding of Gp2 #1, but not Gp2 #5 and #10 
 A competitive binding assay was carried out to assess the impact of 
natural ligands on Gp2 binding. HEK293T cells overexpressing InsR were treated 
with either insulin or IGF-II for 1 hour prior to Gp2 treatments. Gp2 binding was 
evaluated by flow cytometry. Results indicated that insulin, but not IGF-II 
enhanced Gp2#1 binding (Figure 3.17). Neither insulin nor IGF-II impacted 
binding by Gp2 #5 and #10. These results are additional evidence that Gp2 #1 
has a different mode of action than Gp2 #5 and #10.  
Discussion 
Gp2 is a new protein scaffold that is a promising candidate for ligand 
engineering as it offers a smaller size in a robust, stable structural framework 
with a large available binding surface amenable to mutation [194]. Directed 
evolution yielded three Gp2 variants directed against InsR. Notably, all three 
carry a pair of cysteines, located at sites adjacent to each other in the wild-type 
structure, suggesting a disulfide bond in the proteins (Figure 3.1B and 3C). The 
Gp2 variants were able to be produced in T7 express E. coli (Figure 3.4) and 
their monomers showed InsR-specific binding (Figure 3.3) and InsR inhibition in 
breast cancer cells (Figure 3.8 and 3.9).  
Our previous study showed that InsR inhibition alone (using either shRNA, 
small molecule inhibitory insulin analog or anti-InsR antibody) was only effective 
in blocking insulin-stimulated signaling and growth in MCF-7L TamR and T47D 
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TamR, but not their parental cells [198]. In this study, Gp2 variants inhibited 
growth in TamR cells and cell cycle progression in MDA-MB-231. The Gp2 
variants were also able to efficiently block insulin-stimulated cell growth in MCF-
7L parental with some variation in T47D parental cells. However, the signaling 
data in Figure 3.13A and 3.14A suggest that growth effects were not due to short 
term inhibition of InsR biochemical signaling or apoptosis induction. In parental 
cells, single chain of the InsR can exist as holoreceptors or InsR/IGF1R hybrid 
receptors. If InsR was predominantly contained in a hybrid form, then a Gp2 InsR 
specific binder may not inhibit the hybrid. Since the hybrid receptors have high 
affinity for IGF-I, but not insulin, this could explain why the Gp2 binders do not 
blocked IGF action. Additional studies need to be performed to determine if the 
Gp2 binders affect signaling in the TamR cells after long term exposure to 
explain the differences between the signaling and growth results we have shown 
here.  
Gp2 #5 and #10 exhibit similar functional impact on growth, which is 
consistent with their almost identical sequences (an E24K framework mutation in 
#5 is the only difference). Both demonstrated moderate signaling inhibition and 
strong cell growth inhibition. Gp2 #1 appears to operate via a different 
mechanism of action than Gp2 #5 and #10. Unlike Gp2 #5 and #10, Gp2 #1 had 
three significant differences. Gp2 #1 completely blocked IGF-I and insulin-
mediated growth in T47D parental cells, inhibited signaling in a different fashion 
and exhibited positive cooperative binding with insulin, which suggests a unique 
insulin/InsR binding mechanism.  An insignificant reduction on the basal growth 
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in the MCF-7L and MCF-7L TamR cells could possibly be due to indirect effects 
of InsR inhibition on glucose metabolism (Figure 3.8).  
InsR exists in two isoforms: isoform A and B. InsR-A, which lacks 12 
amino acid via alternative splicing of exon 11 is predominantly expressed in fetal 
and cancer cells with high affinity to insulin and IGF-II; whereas, InsR-B is mainly 
expressed in metabolic organs such as adult muscle, liver and fat and binds only 
insulin at physiological concentration [167, 168]. In the cells we used, the 
predominant isoform is InsR-A [130] and further study will be needed to 
determine if the molecules we have described also have high affinity for InsR-B. 
Since Gp2 is one of the smaller protein scaffolds, it may be at advantage in the 
design strategy for targeting against a challenging epitope to develop isoform-
specific binders.  
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Figure 3.1. Structure of Gp2 domain, PDB: 2WNM. (A) The naïve Gp2 library 
was generated by diversifying the two adjacent loops highlighted in red. Segments 
of six, seven, or eight amino acids – randomized using a custom degenerate codon 
(15% A, 15% C, 25% G, 45% T at site 1; 45% A, 15% C, 25% G, 15% T at site 2; 
and 0% A, 45% C, 10% G, and 45% T at site 3) – were permitted. A framework 
mutation (I17V) is also noted. The InsR-evolved Gp2 variants – (B) Gp2 #1, (C) 
Gp2 #5 and #10 contain a pair of cysteines in the loops at site highlighted in green, 
suggesting a potential disulfide bond.   
Wild type: 
KFWATVESS--EHSFEVPIYAETLDEALELAEWQYVPA--GFEVTRVRP 
 
Naïve library: 
KFWATVXXXXXXXXFEVPVYAETLDEALELAEWQYXXXXXXXXVTRVRP 
 
B C 
A 
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Figure 3.2. Identification of InsR-specific Gp2 through yeast surface display 
and directed evolution. (A) Schematic diagram of Gp2 scaffold engineering. 
Blue indicates negative depletion; red indicates InsR positive selection; green 
indicates gene and loop mutations of Gp2, followed by electroporation via 
homologous recombination with linearized yeast surface display pCT vector. (B) 
Yeast surface display of Gp2 libraries against mammalian cell lysates containing 
GFP-conjugated InsR. HEK293T cells were plated, transfected with either InsR-
GFP or GFP-control plasmids and collected as whole cell lysates. Yeast library 
displaying evolved population (–Gp2αInsR) was pre-incubated in either InsR-
GFP or GFP-control contained lysates for 1 hour before labeling for a mouse c-
MYC antibody, followed by AF647-conjugated anti-mouse antibody (Gp2 
expression). Binding of Gp2 to InsR-GFP was detected and isolated by flow 
cytometry. Gp2 against rabbit IgG was used as a Gp2-control and was tested 
against InsR-GFP contained lysates under similar conditions.  
B 
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Figure 3.3. Affinity titration of Gp2 variants. HEK293T lentivirus transduced 
with either pLenti-InsR-GFP or pLent-GFP-ctrl were labeled with increasing 
concentrations of indicated soluble Gp2. Binding was detected by AF647-
conjugated anti-His antibody via flow cytometry. Fluorescence signal was 
subtracted from the basal signal. KD values represented median ± standard 
deviation of three independent experiments. Some data points were not repeated 
and thus no standard deviation indicated. Note that HEK-Ctrl cells express 
modest levels of InsR (Supplementary Figure 2A), which accounts for the non-
zero signal at higher concentrations. 
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Figure 3.4. Verification of Gp2 variants by size and sequencing (A) 
Coomassie blue staining of soluble Gp2 clones. Identified Gp2 variants were 
purified using Ni-NTA resin and size exclusion filter, separated by 15% SDS-
PAGE. The gel was stained with Coomassie blue. (B) Protein sequences of Gp2 
variants. Red indicated as loop mutation; blue indicated as framework mutation 
relative to initial library. 
 
 
 
Gp2 Protein sequences 
WT ASKFWATVESSEHSFEVPIYAETLDEALELAEWQYVPAGFEVTRVRPGSHHHHHH 
#1 ASKFWATVCSGHDGYCFEVPVYAETLDEALELAEWQYDSTYYDYAVTRVRPGSHHHHHH 
#5 ASKFWATVDCLYNDTAFEVPVYAETLDKALELAEWQYDPNYCIVTRVRPGSHHHHHH 
#10 ASKFWATVDCLYNDTAFEVPVYAETLDEALELAEWQYDPNYCIVTRVRPGSHHHHHH 
Blue: framework mutation, Red: loop mutation, underline: Gp2 loops 
B 
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Figure 3.5. Minimal binding of Gp2 control to InsR overexpressed HEK293T 
cells. (A) InsR expression levels in the indicated cells were evaluated with 
antibody via flow cytometry. Cells were labeled with a mouse anti-InsR antibody 
(clone 83-7), followed by a secondary anti-mouse antibody conjugated with 
AF647. Results represent median ± standard deviation of three independent 
experiments. (B) Cells were labeled with 0 µM (-) or 1 µM (+) non-binding control 
Gp2, followed by a secondary fluorescein-conjugated anti-His antibody and 
detected via flow cytometry. Results represented median ± standard deviation, 
n=3 for Gp2-Ctrl labeled cells, n=1 for fluorescein-ctrl labeled cells.   
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Figure 3.6. Minimal binding of InsR-evolved Gp2 variants to IGF1R in MCF-
7Ls. (A) Cells were labeled with a mouse PE-conjugated anti-IGF1R antibody or 
a mouse anti-InsR antibody followed by an AF647-conjugated anti-mouse 
antibody for an hour each at 4C. (B) Cells were labeled with 100 nM of indicated 
Gp2 variants and AF647-conjugated anti-His antibody for an hour each at 4C. 
Bindings were measured via flow cytometry. Values were normalized to their 
respected controls and represented as geometry mean ± standard deviation in 
duplicates. 
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Figure 3.7. Minimal binding of InsR-evolved Gp2 variants to IGF1R in 
T47Ds. (A) Cells were labeled with a mouse PE-conjugated anti-IGF1R antibody 
or a mouse anti-InsR antibody followed by an AF647-conjugated anti-mouse 
antibody for an hour each at 4C. (B) Cells were labeled with 100 nM of indicated 
Gp2 variants and AF647-conjugated anti-His antibody for an hour each at 4C. 
Bindings were measured via flow cytometry. Values were normalized to their 
respected controls and represented as geometry mean ± standard deviation in 
duplicates. 
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Figure 3.8. Inhibition of IGF-II/insulin-stimulated monolayer proliferation in 
MCF-7Ls by Gp2 variants. Cell monolayer growth of (A) MCF-7L and (B) MCF-
7L TamR were measured using MTT proliferation assay. Cells were plated, 
starved for 24 hours and then treated with indicated concentrations of soluble 
Gp2 in combination with either 10 nM insulin, 10 nM IGF-1 or 10 nM IGF-II. Two-
way ANOVA with Bonferroni comparison was performed to identify significance 
among untreated versus treated groups. *, p<0.05; **, p<0.01; ***, p<0.001. 
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Figure 3.9. Differential effects of Gp2 variants on monolayer proliferation of 
T47Ds. Cell monolayer growth of (A) T47D and (B) T47D TamR. Cells were 
serum-starved for 24 hours and treated with indicated concentration of soluble 
Gp2 in combination with either 10 nM insulin, 10 nM IGF-I or 10 nM IGF-II. 
Readings were taken 4 days later and the values were represented as mean ± 
standard deviation in triplicates. Two-way ANOVA with Bonferroni comparison 
was performed to identify significance among untreated versus treated groups. 
**, p<0.01; ***, p<0.001.    
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Figure 3.10. Minimal effects of Gp2 control on monolayer proliferation 
growth. Gp2 against rabbit IgG was used as a Gp2 control in affecting cell 
growth in MCF-7L and MCF-7L TamR. Readings were taken 5 days later and the 
values were represented as mean ± standard deviation in triplicates. Two-way 
ANOVA with Bonferroni comparison was performed to identify significance 
among untreated versus treated groups. NS, not significant; 
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Figure 3.11. Inhibitory effects of Gp2 variants on the distribution of cell cycle 
phases in MDA-MB-231.  
Cells were serum-starved for 24 hours and treated with either 200 nM of indicated 
soluble Gp2 alone or in combination with either 20 nM insulin or 10 nM IGF-I 
overnight. Cell cycle analysis was performed using flow cytometry. Two 
independent experiments were carried out and both showed consistent outcomes. 
Representative data is presented.   
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Figure 3.12. Minimal apoptosis effects of Gp2 variants in breast cancer 
cells. Cells were serum-starved overnight and treated with either 200 nM of 
indicated soluble Gp2 alone, in combination with 20 nM insulin or doxurubicin 
(DOX) as a positive control for 2 days. Cleaved PARP was measured using flow 
cytometry and the values represented as geographic mean ± standard deviation 
of duplicates from two independent experiments.  
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Figure 3.13. Differential signaling effects of Gp2 variants on insulin/IGF 
signaling in MCF-7L. (A) MCF-7L and (B) MCF-7L TamR cells were plated, 
serum-starved overnight, pre-treated with indicated concentrations of Gp2 
overnight before treating with either 10 nM IGF-I, 10 nM IGF-II or 10 nM insulin 
for 15 minutes. Whole cell lysates were separated by SDS-PAGE and 
immunoblotted with indicated antibodies.   
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Figure 3.14. Differential signaling effects of Gp2 variants on insulin/IGF 
signaling in T47Ds.  
(A) T47D and (B) T47D TamR cells were plated, serum-starved overnight, pre-
treated with indicated concentrations of Gp2 for 4 hours before treating with 
either 10 nM IGF-I, 10 nM IGF-II or 10 nM insulin for 15 minutes. Whole cell 
lysates were separated by SDS-PAGE and immunoblotted with indicated 
antibodies.   
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Figure 3.15. Differential signaling effects of Gp2 variants on triple negative 
breast cancer cells.  
MDA-MB-435 and MDA-MB-231 cells were plated, serum-starved and pre-
treated with 200 nM of indicated soluble indicated Gp2 overnight before treating 
with either 10 nM insulin or 5 nM IGF-I for 15 minutes. Whole cell lysates were 
collected, separated by 8% SDS-PAGE and blotted for indicated antibodies. 
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Figure 3.16. The abundance of IGF1R/InsR hybrid receptors attributed to 
the differential signaling effects on Gp2 variants in different breast cancer 
cell lines.   
Whole cell lysates of indicated cell lines were collected and immunoprecipitated 
with either a mouse anti-InsR antibody or a control mouse IgG overnight. 
Immunoprecipitation were resolved using SDS-PAGE and subjected for IGF1R 
immunoblotting. FL stands for “flow through”, representing the supernatant of 
anti-InsR immunoprecipitation. 
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Figure 3.17. Non-competitive binding of Gp2 variants against InsR. 
HEK293T pLenti-InsR-GFP cells were trypsinized and pre-incubated with either 1 
µM of insulin or IGF-II for 1 hour before labeling with 100 nM Gp2 variants, 
followed by AF647-conjugated anti-His antibody. Binding was measured using 
flow cytometry. Results represented adjusted median ± standard deviation in 
triplicates, where the basal values were subtracted from all samples. Paired two-
tailed t tests were used to compare Gp2-labeled versus ligands-Gp2-labeled 
samples.  NS, not significant; **, p<0.01.  
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Chapter 4 
 
Concluding remarks and future studies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
100 
 
Conclusion  
 In summary, the generation of endocrine resistant models by a former 
colleague in the lab, Dedra Fagan, Ph.D. provided evidence for the inefficacy of 
IGF1R blocking agents in treating endocrine resistant breast cancer patients due 
to the lack of IGF1R expression. The highly homologous receptor, InsR which 
has been neglected as a potential target remains intact and can fully compensate 
for IGF1R signaling. Data from the first part of the work highlighted the role of 
InsR in breast cancer biology, especially in the context of resistance to endocrine 
therapies in breast cancer. Several InsR-selective agents, from a short hairpin 
RNA, small peptide, antibody to engineered small scaffolds have consistently 
shown effective blockage of endocrine resistant breast cancer growth. InsR 
inhibition may potentially be beneficial in suppressing triple negative breast 
cancer, especially in cancers expressing IGF1R/InsR receptors. As mentioned, 
hyperinsulinemia resulted from anti-IGF1R blockage may promote insulin-driven 
growth and thereby partially contributed to the disappointing clinical results 
testing anti-IGF1R monoclonal antibodies.  
 The second part of the work demonstrated small InsR-evolved Gp2 
variants not only exhibited strong binding affinity to InsR, but also promising 
biological outcomes in breast cancer cells. The data also indicated some 
interesting characteristics of Gp2#1 that worth pursuing in the future, including 
the possibility of binding a second receptor other than InsR and also the 
capability to bind the activated Insulin/InsR complex. This observation is, 
however, not noticeable with Gp2#5 and #10, suggesting that Gp2#1 might have 
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some unique functions, while Gp2#5 and #10 might work similarly to other InsR-
selective inhibitors.  
Overall, targeting InsR is needed to completely disrupt the IGF1R/InsR 
network, which is especially evident in endocrine resistant breast cancers. 
Whether InsR inhibition could overcome primary (de novo) endocrine resistance 
or treat secondary (acquired) resistance, it is not certain. The continued function 
of InsR may explain why targeting IGF1R was unsuccessful in phase III clinical 
trials. InsR inhibition is slowly being recognized as an important pathway to 
inhibit as cumulative studies, including those from our group, have emphasized 
the expression of this receptor in breast cancer. The emergence of precision 
medicine also increasingly recognizes the development of new cancer 
interventions that may one day improve clinical outcomes.  
Future directions 
 While this thesis mainly focuses on the generation of InsR-binding 
scaffolds and in vitro studies, many opportunities are awaiting to be discussed 
and pursued. This section presents some of the directions for future 
investigations:  
Choices of combinatorial treatments 
Studies from my first part of work suggested the use of HuEM164 and 83-7 mAbs 
did not show synergistic inhibitory effects. Non-specific agonism of 83-7 mAb 
was also observed in endocrine-sensitive breast cancer cells. This observation 
needs to be verified in the TNBC lines. It is also unsure whether 83-7 mAb 
interferes with HuEM164 efficacy or its non-specific agonism is sufficient to 
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overcome HuEM164 inhibition. As an alternative, Gp2#5 or Gp2#10 could be 
used in combination with anti-IGF1R mAb. Single agent inhibition of Gp2 variants 
has only been tested so far and their combination efficacy with anti-IGF1R 
remains elusive.  
Epitope mapping  
The binding capability of these Gp2 variants to InsR has been demonstrated, 
however their sole specificity has yet to be determined. Current data suggested 
that Gp2#5 and Gp2#10 may be specific against InsR, while Gp2#1 may have 
weak affinity to IGF1R. This speculation can be confirmed in InsRnull cells with 
either IGF1Rhigh or IGF1Rlow cell lines. In addition, the epitope of these Gp2 
variants are unknown. Gp2#5 and Gp2#10 do not seem to share the same 
epitopes as the natural ligands, suggesting allosteric inhibitory actions of Gp2#5 
and #10. Competitive binding assay also showed an unexpected binding 
phenomenon of Gp2#1 with the possibilities to bind either receptor-ligand 
complex or the activated conformation of InsR. Thus, epitope mapping will shed 
light on some of these questions. Some experiments can be done including 
competitive binding assay among these Gp2 variants in the presence or absence 
of natural ligands (mainly to determine whether activated conformation of InsR is 
required for Gp2#1 binding). Crystal structures of these Gp2/InsR can certainly 
identify the exact epitopes and other physical properties. Theoretically, 
mammalian cell surface panning could potentially be explored, where a library of 
mammalian cells displaying InsR with few mutations on every 10-amino-acid 
segment on the ectodomain of the receptors can be used for binding screening. 
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The loss of binding function due to the mutations at certain regions could indicate 
potential epitopes of the binders.  
Mechanism of action 
The differential signaling outcomes from these Gp2 variants in different breast 
cancer cell lines could due to two main reasons: 1.) the differential mechanistic 
action of these Gp2 variants and 2.) abundance and stoichiometry of 
holoreceptors versus hybrid receptors in different cell lines. Although some InsR 
downstream signaling studies have been conducted, the story is not fully 
understood. Do these Gp2 involve additional pathways other than MAPK and 
PI3K pathways? How do they affect insulin/InsR gene signature and downstream 
signaling cascades?  
In vivo studies 
Few studies have shown InsR inhibition in animal models. Rats treated with S961 
has shown hyperinsulinemia, hyperglycemia and insulin-mediated glucose 
intolerance, however these side effects were restored by an anti-diabetic drug, 
peroxisome-proliferator-activated receptor gamma (PPARγ) agonist – 
pioglitazone [200]. While the IGF1R/InsR tyrosine kinase inhibitor has been 
evaluated in a mouse model of type 2 diabetes, this drug clearly made glucose 
control worse [129]. If InsR inhibitors are to be translated into the clinic, some of 
the questions including dose, schedule, potential systemic and metabolic 
toxicities need to be answered in an in vivo setting. Since metabolic toxicity is the 
main concern, the combination use of metformin may address hyperglycemia 
condition resulted from InsR inhibition. Perhaps, an intermittent treatment 
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between metformin and InsR inhibitor may be a better dosing approach to 
prevent uncontrolled hyperglycemia.  
Protein engineering against InsR-A or hybrid receptor 
In the long run, it would be valuable to target the mitogenic form of InsR – InsR-
A, leaving the metabolic isoform B InsR unperturbed. No InsR isoform specific 
antibody or binding agent has been reported. It is certainly challenging from a 
protein engineering perspective as InsR-A lacks only 21 amino acids at a less 
prominent region. Nevertheless, it is feasible if we have the representative target 
system and reliable/stable protein library. These Gp2 variants may be a useful 
platform for the evolution of isoform-specific binders. Mammalian cell lines 
expressing either InsR-A or InsR-B conjugated to respective fluorescent tags 
need to be generated to serve as a necessary reagent to begin screening. 
Biotinylated recombinant receptors may be used initially to select binders from a 
library, however this approach has a chance of losing potential translatable 
binders. Once the cell lines are generated, the screening/panning process using 
yeast surface display will need to be less stringent at the beginning until we are 
confident with the enriched population of the binders. Similarly, there are no 
efficient methods to quantitatively or qualitatively measure the level of 
IGF1R/InsR hybrid receptors. Thus, it will certainly be a motivation in the future to 
engineer and identify a molecular binder against IGF1R/InsR hybrid receptor.  
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Cell lines and culture 
MCF-7L and T47D are human ER-positive breast cancer cell lines. MCF-
7L (parental cell line) was kindly provided by C. Kent Osborne (Baylor College of 
Medicine, Houston, TX) and maintained in improved MEM Richter’s modification 
medium (zinc option) supplemented with 5% FBS, and 11.25 nM insulin. MCF-7L 
karyotyping and gene expression profiling have shown that these cells are 
consistent with the originally described cell line (data not shown). T47D (parental 
cell line) was obtained from ATCC and maintained in MEM supplemented with 
5% FBS, 1X nonessential amino acids and 6 ng/mL insulin. MCF-7L TamR and 
T47D TamR cells were generated as described [148]. MCF-7L TamR cells were 
maintained in phenol-red free IMEM (zinc option) supplemented with 11.25 nM 
insulin, 5% charcoal/dextran-treated FBS and 100 nM 4-OH tamoxifen; while 
T47D TamR cells were maintained in phenol-red free IMEM supplemented with 6 
ng/mL insulin, 1X nonessential amino acids, 5% charcoal/dextran-treated FBS 
and 100 nM 4-OH tamoxifen.  MDA-MB-231, MDA-MB-435 and HEK293T cells 
were obtained from ATCC and maintained in HyCloneTM Dulbecco’s Modified 
Eagle Medium (GE Healthcare Life Science) supplemented with 10% FBS. All 
cells were grown at 37°C in a humidified atmosphere containing 5% CO2. All 
growth media were supplemented with 100 U/mL penicillin and 100 µg/mL 
streptomycin and purchased from Gibco®.  
Reagents 
 IGF-I, IGF-II and insulin were purchased from Gemini and Eli Lily, 
respectively. Puromycin solution was purchased from Sigma-Aldrich.  Geneticin 
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(G418 sulfate) solution was purchased from Life Technologies. Humanized anti-
IGF1R monoclonal antibody HuEM164 was generously provided by Immunogen 
Inc. Anti-InsR monoclonal antibody, alpha subunit clone 83-7 was purchased 
from EMD Millipore. S961 peptide was generously provided by Novo Nordisk, 
Denmark [158]. 
Antibodies 
Antibodies for total IGF1R (#3027), phosphorylated IGF1R tyrosine 1135 
(#3918), phosphorylated AKT serine 473 (#9271) and threonine 308 (#9275), 
total p44/42 MAPK (#9102), phosphorylated p44/42 MAPK (#4376), 
phosphorylated p70 S6 kinase (#9205) used in immunoblotting were purchased 
from Cell Signaling Technology. Normal mouse IgG (sc-2025), InsR antibody for 
immunoprecipitation (sc-57342) and InsR antibody for immunoblotting (sc-711) 
were purchased from Santa Cruz Biotechnology.  Horseradish peroxidase-
conjugated anti-phosphotyrosine (pY-20) was purchased from BD Transduction 
Lab. (#610012). Anti-rabbit horseradish peroxidase-conjugated secondary 
antibody was purchased from Pierce.  
Generation of stable InsR knockdown with shRNA 
Lentiviral pLKO.1 vectors encoding either InsR mRNA specific short 
hairpin RNA (shRNA) sequences or vector controls were purchased from Open 
Biosystems through BioMedical Genomics Center at the University of Minnesota, 
Minneapolis, MN. Two different constructs of shRNA against InsR are described 
as shIR#2 and shIR#6. Their full sequences are respectively 
CCGGCACTGATTACTTGCTGCTCTTCTCGAGAAGAG 
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CAGCAAGTAATCAGTGTTTTT and 
CCGGCTCAGGATTCTCACGACTCTACTCGAGT 
AGAGTCGTGAGAATCCTGAGTTTTT. Lentivirus production was carried out in 
HEK293T packaging cells and the viral particles were used to transduce MCF-7L 
and T47D cells. Final concentration of 10 µg/mL polybrene was used to increase 
transduction efficiency. Cells underwent puromycin selection and were 
maintained in 2 µg/mL for MCF-7L and MCF-7L TamR; 1.5 µg/mL for T47D 
parental cells and 15 µg/mL for T47D TamR.  
Overexpression of insulin receptor 
 pEGFP-N2 vector containing full length human InsR cDNA was obtained 
from Addgene (#22286) [201] and transiently transfected into MCF-7L and MCF-
7L TamR using Lipofectamine 2000 (Invitrogen) according to manufacturer’s 
protocol. Cells were selected and maintained in 500 µg/mL G418 for a week 
before re-plating for immunoblotting analysis or monolayer growth assay.  
Immunoblotting analysis 
 Cells were plated at a density of 3 x 105 cells in 60 mm diameter dishes 
and allow to equilibrate overnight. Full medium was replaced with serum-free 
medium (SFM) for 24 hours. Cells were then treated, washed twice with ice-cold 
PBS and lysed with lysis buffer of 50 mM Tris-Cl (pH 7.4), 1% Nonidet P-40, 2 
mM EDTA (pH 8.0), 100 mM NaCl, 10 mM sodium orthovanadate, and with 
complete proteases inhibitor cocktail (Roche Diagnostics). Lysates were 
centrifuged at 12,000 g for 30 minutes at 4°C. Protein concentrations were 
measured using bicinchoninic acid protein assay reagent kit (Pierce).  Whole cell 
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lysates (50 µg) were boiled in 5X Laemmli loading buffer, separated by 8% SDS-
PAGE, transferred to PVDF membrane and immunoblotted according to 
manufacturer guidelines. For Immunoprecipitation (IP), whole-cell lysates were 
incubated with either anti-InsR antibody or mIgG overnight at 4°C. Protein A/G 
PLUS-Agarose bead slurry was added into the samples and incubated for 4 
hours at 4°C. Beads were washed with lysis buffer 5 times and boiled in 5X 
Laemmli loading buffer. Samples were resolved by 8% SDS-PAGE, transferred 
to PVDF membrane and immunoblotted. 
Reverse transcription and quantitative real-time PCR 
 Cells were seeded at a density of 2 x 105 cells in 6-well plates in growth 
media until reaching 80% confluent. Cellular RNA was isolated using TriPure 
Reagent according to the manufacturer (Roche). For RNA quality verification, a 
ratio of 260 nm to 280 nm was determined. A total of 1 µg of RNA was reverse 
transcribed using qScript cDNA synthesis kit (Quanta Biosciences), and 
quantitative PCR was performed using the University SYBR Green Kit according 
to the manufacturer’s protocol (Roche) on an Eppendorf Mastercycler Realplex 
machine. The relative abundance of InsR mRNA was calculated using cycle 
threshold values that were derived from a standard curve and normalized to 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) level as an internal 
control. The forward and reverse primers are as followed: InsR 5’-
CAACGTGGTTTTCGTCCCC-3’ and 5’-AGATGACCAGCGACTCCTTG-3’; 
GAPDH 5’-TGAAGGTCGGAGTCAACGATTTGGT-3’ and 5’-
GAAGATGGTGATGGGATTTC-3’ 
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Monolayer growth assay 
 Cells were plated at a density of 15,000 cells per well in 24-well plates and 
allowed to attach overnight. Full media were replaced and starved with SFM for 
24 hours. After 5 or 6 days of treatment, growth was assessed via MTT assay. 
Each well was added 60 µL of 5 mg/mL thiazolyl blue tetrazolium bromide 
solution (MTT) from Sigma-Aldrich in SFM for 4 hours at 37°C in dark. Media 
were aspirated and purple formazan crystals were lyzed with 500 µL of 
solubilization solution (95% dimethylsulfoxide and 5% Improved MEM). 
Absorbance was measured with a plate reader at 570 nm using a 650nm 
differential filter to access growth.  
Anchorage-independent growth assay (soft agar) 
 A 1-mL layer of 0.8% SeaPlaque-agarose (bioWhittaker) in 1% FBS-
containing growth media was solidified into each well of a 6-well plate. The 
bottom layer was overlaid with 1mL of 0.5% top agar mixture for 15,000 cells per 
well with appropriate treatment. All plates were incubated at 37°C. The number of 
colony formation was assessed on a light microscope with an ocular grid. Only 
colonies exceeding two thirds of grid square were scored. Five random fields 
were counted per well.    
Cell cycle analysis 
 Cells were plated at density of 8 x 105 cells in 60 mm dishes, starved with 
SFM for 24 hours and treated overnight. Cells were trypsinized, washed twice 
with ice-cold PBS containing 1% bovine serum albumin (BSA) and re-suspended 
with staining buffer (PBS containing 0.1 mg/mL propidium iodide, 0.5% triton X-
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100, 16 µg/mL RNase, 1% BSA) for 2 hours. Cell cycle analyses were performed 
for DNA content using BD Accuri C6 flow cytometry. Single cells were gated and 
10,000 events were collected. The proportion of cells in G0G1, S and G2/M 
phases was quantified using FlowJo software.  
Binder Selection and Directed Evolution 
The naïve Gp2 library contains 4x108 unique variants in which the 
sequences of two adjacent loops are diversified to six to eight amino acids with 
composition biased to mimic natural antibody repertoires (17% tyrosine, 13% 
serine, 11% aspartic acid, 9% asparagine, 6% alanine and histidine, 5% cysteine 
and threonine, 4% glycine and proline, 3% phenylalanine, arginine, valine,2% 
leucine, isoleucine, glutamic acid, lysine, 1% glutamine, tryptophan and <1% 
methionine) [194]. Binder selection and directed evolution were generally 
adopted from [194, 202]. Recombinant insulin receptor ectodomain (rInsR) (R&D 
Systems, Minneapolis MN), which served as a target antigen for screening, was 
biotinylated with EZ-link® NHS-PEG4-Biotin (Thermo Scientific, Rockford IL) 
resulting in nine biotin moieties per receptor. Yeast displaying the naïve Gp2 
library underwent magnetic sorting, which consisted of two negative depletions 
(first with avidin-coated beads, then beads with immobilized biotinylated 
transferrin) to remove any non-specific binders, followed by a positive selection 
to enrich binders to immobilized biotinylated rInsR. Magnetic sorts on the naïve 
library were performed at 4°C with two washes during rInsR selections. Bound 
yeast were grown, re-induced and sorted more stringently with another round of 
magnetic sorting (two depletions and positive selection, as above) at room 
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temperature with three washes. The resultant population was sorted by flow 
cytometry to isolate full length Gp2 mutants. Induced yeast were labeled with 10 
µg/mL mouse anti-c-MYC antibody (9E10, BioLegend, San Diego CA) followed 
by 10 µg/mL fluorescein-conjugated goat anti-mouse antibody (Sigma Aldrich, St. 
Louis, MO). All fluorescein-positive yeast were collected via BD FACS Aria II. 
Sorted yeast were grown and plasmid DNA was extracted using Zymoprep yeast 
plasmid miniprep kit II (Zymo Research Corp., Irvine CA). The enriched Gp2 
population was diversified by random mutagenesis to the full gene and the loops 
of Gp2 in parallel via error-prone PCR using nucleotide analogs 2’-deoxy-P-
nucleoside-5’-triphosphate and 8-oxo-2’-deoxyguanosine-5’- triphosphate (Trilink 
Biotechnologies, San Diego CA) [203]. Mutant genes and gene fragments were 
retransformed into yeasts via electroporation with homologous recombination 
with linearized pCT vector. The process results in shuffling of mutated Gp2 loops. 
The mutagenized Gp2 population underwent two rounds of magnetic 
sorting (both with three washes at room temperature), one flow cytometry sort 
against biotinylated rInsR and one flow cytometry sort against mammalian cell 
lysates expressing GFP-conjugated InsR. For first flow cytometry sort, the yeast 
library was labeled with anti-c-MYC antibody 9E10 and 50 nM biotinylated rInsR, 
followed by fluorescein-conjugated goat anti-mouse antibody and Alexa Fluor 
647 (AF647)-conjugated streptavidin (Life Technologies, Eugene, OR). Yeast 
clones that showed double positive signals for fluorescein and AF647, indicating 
full length Gp2 expression and rInsR binding, were collected.  To ensure selected 
Gp2 clones showed consistent binding capacity to cell surface InsR, the yeast 
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population underwent another round of flow cytometry against mammalian cell 
lysates [204]. HEK293T cells were plated, transiently transfected with InsR-GFP 
plasmid (Addgene #22286) using Lipofectamine 2000 (Life Technologies) 
according to manufacturer’s protocol and lysed (1% Triton-X, 2 mM EDTA, 1x 
protease inhibitor in PBS). Plasmid expressing GFP alone (Addgene #19319) 
was used to create a GFP control. The induced yeast population was incubated 
in the cell lysate expressing either InsR-GFP or GFP-control for one hour, 
washed twice with cold 1% PBSA (1% bovine serum albumin in PBS) and 
labeled with 9E10 and AF647-conjugated anti-mouse antibodies.  All yeast 
clones that showed GFP and AF647 signals were collected.  
 This enriched Gp2 population underwent mutagenesis and two rounds of 
flow cytometry sorts against cell lysates (two fold diluted relative to the first cell 
lysate sort) for affinity maturation. For each sort, yeast exhibiting the top 2% of 
GFP:AF647 ratio (InsR binding per displayed Gp2) were collected. These cells 
were grown and zymoprepped to isolate plasmid DNA. Clonal plasmid was 
obtained by transforming extracted DNA into E.coli One Shot® TOP10 E. coli 
(Invitrogen, Carlsbad, CA). Single colonies were grown in LB medium and 
miniprepped (Invitrogen, Carlsbad, CA). Purifed DNA was sequenced by Eurofins 
Genomics (Huntsville, AL).  
Gp2 production and purification 
NheI and BamHI restriction enzymes were used to transfer the Gp2 gene 
from pCT yeast surface display vector into a pET vector with a C-terminal His6 
tag (Novagen, EMD Milipore, Billerica, MA). The resultant plasmids were 
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transformed into T7 express competent E. coli and grown in LB medium 
containing 100 µg/mL kanamycin. One liter of LB medium was inoculated with 5 
mL of overnight culture, grown at 37°C to an optical density at 600nm of 0.6-1.0 
units, and induced with 0.5 mM isopropyl β-D-1-thiogalactopyranoside overnight 
at 20°C. Cells were pelleted, resuspended in 20 mL of lysis buffer (50 mM 
sodium phosphate, pH 8.0, 0.5 M sodium chloride, 5 mM 3-[(3-
cholamidopropyl)dimethylammonio]-1-propanesulfonate, 25 mM imidazole) and 
underwent five freeze-thaw cycles. The soluble fraction was isolated by 
centrifugation at 10,000 g for 40 min at 4°C and filtered through a 0.45 µm 
syringer filter. Gp2 was purified by nickel-nitrilotriacetic acid affinity 
chromatography (Qiagen, Hilden, Germany) and by size exclusion/gel filtration 
chromatography using PD-10 column packed with Sephadex G-25 (GE 
Healthcare Bio-Sciences, Pittsburgh, PA) 
Affinity titration 
Lentiviral pLenti-InsR-GFP containing full length human InsR cDNA and 
control vector were purchased from Applied Biological Materials Inc. (British 
Columbia, Canada). They were referred to InsR-GFP and GFP-ctrl, respectively 
and were used to generate stable InsR overexpressing cell lines. Lentivirus 
production and transduction were carried out in HEK293T cells with 10 µg/mL 
polybrene to increase transduction efficiency. Cells underwent selection and 
were maintained in 2 µg/mL puromycin (Sigma-Adrich, St. Louis, MO). Stable 
HEK293T cell lines with either GFP-tagged InsR overexpression or GFP-control 
were labeled with soluble Gp2 at increasing concentrations for one hour at 4°C, 
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washed with PBSA and labeled with AF647-conjugated anti-His5 antibody 
(Qiagen, Valencia, CA) for one hour at 4°C. Fluorescence was analyzed on a BD 
Accuri C6 flow cytometer and quantified using FlowJo software. The equilibrium 
dissociation constant, KD,  was determined by minimizing the sum of squared 
errors assuming a 1:1 binding interaction.  
Cell surface binding assay 
Cells were detached using trypsin, washed with PBS, labeled with soluble 
Gp2 at varying concentrations for one hour at 4°C, washed with cold PBSA and 
labeled with AF647-conjugated anti-His5 antibody for one hour at 4°C. An anti-
InsR antibody, clone 83-7 (hybridoma was kindly provided by Ken Siddle from 
University of Cambridge, UK) was used as a positive control for cell surface 
receptor binding. Fluorescence was analyzed on a BD Accuri C6 flow cytometer 
and quantified using FlowJo software.  
Detection of cleaved Poly ADP-Ribose Polymerase (PARP) 
Cells were plated at density of 6 x 105 cells in 60 mm dishes, serum-
starved overnight and treated for 2 days. Cells were trypsinized, washed twice 
with ice-cold PBS with 1% BSA and resuspended in fixation/permealization 
solution (BD cytofix/cytopermTM, BD Bioscience, San Diego CA) for 30 minutes. 
These fixed cells were stained with cleaved PARP, Asp214 rabbit antibody 
(#5625, Cell Signaling Technology), followed by an AF647-conjugated anti-rabbit 
antibody (Life Technologies) for an hour each at 4C. Fluorescence was 
analyzed on a BD Accuri C6 flow cytometry and quantified using FlowJo 
software. 
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Competitive binding assay 
HEK293T cells transduced with pLenti-InsR were trypsinized, washed with PBS 
and pre-treated with or without insulin or IGF-II in 1% PBSA at 4°C for one hour. 
Cells were then labeled with Gp2 followed by AF-647 conjugated anti-His5 
antibody at 4°C for one hour each. Fluorescence signal was detected using BD 
Accuri C6 flow cytometer and analyzed using FlowJo software.  
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